4D Molecular Therapeutics Announces Preclinical Data Presentations at ASGCT and ATS Annual Meetings on Three Wholly-Owned Product Candidates from Non-Human Primate Studies


– Abstracts on 4D-150 for wet AMD/DME and 4D-310 for Fabry disease accepted for oral presentations at ASGCT 24


th

Annual Meeting


– Abstract on 4D-710 for cystic fibrosis lung disease accepted for oral presentation at ATS 2021 International Conference

EMERYVILLE, Calif., April 27, 2021 (GLOBE NEWSWIRE) — 4D Molecular Therapeutics (Nasdaq: FDMT), a clinical-stage gene therapy company harnessing the power of directed evolution for targeted gene therapies, announced preclinical data presentations from non-human primate (NHP) studies at two upcoming medical meetings, the American Society for Gene and Cell Therapy (ASGCT) 24th Annual Meeting, held virtually from May 11 – 14 and the American Thoracic Society (ATS) 2021 International Conference, held virtually from May 14 – 19. The data presentations will address three of the company’s wholly-owned product candidates leveraging three distinct targeted and evolved vectors across three therapeutic areas: 4D-150 for the treatment of wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME), 4D-310 for the treatment of Fabry disease and 4D-710 for the treatment of cystic fibrosis lung disease.

For the first-time, 4DMT will describe the design of 4D-150’s three distinct anti-angiogenic mechanisms and will present preclinical data demonstrating highly significant efficacy, durable aqueous anti-VEGF levels within the NHP eye, safety and tolerability in the laser-choroidal neovascularization (CNV) model.

Details for the presentations at each conference are as follows:

ASGCT 24

th

Annual Meeting

Abstracts are available online and presentations and posters will be accessible through ASGCT’s website at www.asgct.org.

Abstract Title: A Multi-Mechanistic Anti-Angiogenic AAV Gene Therapy Product Candidate, 4D-150, for the Treatment of Wet Age-Related Macular Degeneration (wAMD) and Diabetic Macular Edema (DME): Intravitreal Biodistribution, Transgene Expression, Safety and Efficacy in Non-Human Primates
Session Type: Oral Presentation
Session Date/Time: Wednesday May 12, 2021 5:30 PM – 7:15 PM EDT
Session Title: AAV Biology, Engineering, Immunology and Animal Modeling
Abstract number: 64

Abstract Title: A Targeted AAV Gene Therapy Product Candidate, 4D-310, for the Treatment of Fabry Disease: Intravenous Biodistribution, Transgene Expression and Safety in Non-Human Primates
Session Type: Oral Presentation
Session Date/Time: Friday May 14, 2021 12:15 PM – 2:00 PM EDT
Session Title: Gene Therapy for Lysosomal Storage Disorders
Abstract number: 220

ATS 2021 Annual Conference

Abstracts are available online and presentations and posters will be accessible through ATS’s website at conference.thoracic.org.

Abstract Title: Identification and Characterization of a Novel AAV Capsid and Product for the Treatment of Cystic Fibrosis
Session Type: Mini Symposium (Oral)
Session Date/Time: Sunday May 16, 2021 1:30 PM – 3:00 PM EDT
Session Title: A010 Novel Discoveries in Lung Biology
Abstract number: A1043

Abstract Title: Development of Novel AAV-Based Gene Therapy for Cardiac Disease
Session Type: Thematic Poster Session
Session Date/Time: On Demand
Session Title: TP083 Hey Jude – Novel Findings from Omic and Bioinformatic approaches in Pulmonary Hypertension
Abstract Number: A3624

About 4DMT

4DMT is a clinical-stage company harnessing the power of directed evolution for targeted gene therapies. 4DMT seeks to unlock the full potential of gene therapy using its platform, Therapeutic Vector Evolution, which combines the power of directed evolution with approximately one billion synthetic capsid sequences to invent evolved vectors for use in targeted gene therapy products. The company is initially focused in three therapeutic areas: ophthalmology, cardiology, and pulmonology. The 4DMT targeted and evolved vectors are invented with the goal of being delivered through clinically routine, well-tolerated and minimally invasive routes of administration, transducing diseased cells in target tissues efficiently, having reduced immunogenicity and, where relevant, having resistance to pre-existing antibodies. 4DMT is currently conducting three clinical trials: 4D-125 is in a Phase 1/2 clinical trial for XLRP patients, 4D-110 is in a Phase 1 clinical trial for choroideremia patients and 4D-310 is in a Phase 1/2 clinical trial for Fabry disease patients.

4D Molecular Therapeutics™, 4DMT™, Therapeutic Vector Evolution™, and the 4DMT logo are trademarks of 4DMT.

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, implied and express statements regarding plans and timelines for the clinical development of 4D-310, 4D-125, 4D-110, 4D-150 and 4D-710, including the therapeutic potential and clinical benefits thereof; and 4DMT’s strategy, business plans and focus. The words “may,” “might,” “will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,” “intend,” “believe,” “expect,” “estimate,” “seek,” “predict,” “future,” “project,” “potential,” “continue,” “target” and similar words or expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this press release are based on management’s current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation, risks associated with: the impact of COVID-19 on countries or regions in which we have operations or do business, as well as on the timing and anticipated results of our clinical trials, strategy and future operations; the delay of any current or planned clinical trials for the development of 4DMT’s drug candidates, the risk that the results of our clinical trials may not be predictive of future results in connection with future clinical trials; 4DMT’s ability to successfully demonstrate the safety and efficacy of its drug candidates; the timing and outcome of our planned interactions with regulatory authorities; and obtaining, maintaining and protecting our intellectual property. These and other risks and uncertainties are described in greater detail in the section entitled “Risk Factors” in 4DMT’s most recent Annual Report on Form 10-K filed March 25, 2021, as well as any subsequent filings with the Securities and Exchange Commission. In addition, any forward-looking statements represent 4DMT’s views only as of today and should not be relied upon as representing its views as of any subsequent date. 4DMT explicitly disclaims any obligation to update any forward-looking statements. No representations or warranties (expressed or implied) are made about the accuracy of any such forward-looking statements.

4D-310, 4D-125 and 4D-110 are our product candidates in clinical trials and have not yet been approved for marketing by the US FDA or any other regulatory authority. No representation is made as to the safety or effectiveness of 4D-310, 4D-125, or 4D-110 for the therapeutic use for which they are being studied.

Contacts:

Media:

Theresa Janke
[email protected]

Investors:

Mike Zanoni
Endurance Advisors
[email protected]

 



Freeline to Present Data at the American Society of Gene and Cell Therapy Annual Meeting 2021

LONDON, April 27, 2021 (GLOBE NEWSWIRE) — Freeline Therapeutics Holdings plc (Nasdaq: FRLN) (the “Company” or “Freeline”), a clinical-stage biotechnology company developing transformative gene therapies for patients suffering from inherited systemic debilitating diseases, today announced that the Company will give six poster presentations at the American Society of Gene and Cell Therapy Annual Meeting 2021, taking place May 11 – 14.

“We are excited to be presenting six posters at the upcoming ASGCT conference, which together highlight the scientific foundation that underlies our gene therapy programs and broader platform technology,” said Theresa Heggie, CEO of Freeline. “These posters are reflective of steady progress at Freeline, which we expect will include three gene therapies in the clinic by year end.”  

Poster Presentation Details

#329: FLT201, a Novel Investigational AAV-Mediated Gene Therapy Candidate for Gaucher Disease Type 1 
Presenter:  Romuald Corbau, PhD, Chief Scientific Officer

#509: GLA Uptake and Metabolic Cross Correction in Fabry Disease Relevant Cell Lines: A Rationale for Liver-Directed AAV Gene Therapy 
Presenter: Jey Jeyakumar, PhD, Scientific Director 

#821: Development of a 96-Well Plate-Based High-Throughput System for rAAV Manufacturing Platform Optimization and Candidate Selection 
Presenter: Bettina Prieler, PhD Student Technology Development 

#843: Development and Scale Up of a Suspension Cell-Based AAV Manufacturing Process 
Presenter: Ahmed Youssef, Team Leader USP Development 

#878: 

Defining a Reliable Quantification Assay Strategy for Adeno-Associated Virus (AAV)-Based Gene Therapies
 
Presenter: Felicia Thoennissen, PhD, Scientist Analytical Development 

#894: Development of an Assay to Measure Transduction Efficiency of Adeno-Associated Virus (AAV)-Based Gene Therapies 
Presenter: Anita Heinlein, Scientist Analytical Development 

Abstracts will be available on the ASGCT website starting today.

About Freeline Therapeutics

Freeline is a clinical-stage biotechnology company developing transformative adeno-associated virus (“AAV”) vector-mediated systemic gene therapies. The Company is dedicated to improving patient lives through innovative, one-time treatments that provide functional cures for inherited systemic debilitating diseases. Freeline uses its proprietary, rationally-designed AAV vector, along with novel promoters and transgenes, to deliver a functional copy of a therapeutic gene into human liver cells, thereby expressing a persistent functional level of the missing protein into the patient’s bloodstream. The Company’s integrated gene therapy platform includes in-house capabilities in research, clinical development, manufacturing and commercialization. The Company has clinical programs in Hemophilia B and Fabry disease, as well as preclinical programs in Gaucher disease and Hemophilia A. Freeline is headquartered in the UK and has operations in Germany and the US.

Forward-Looking Statements

This press release contains statements that constitute “forward looking statements” as that term is defined in the United States Private Securities Litigation Reform Act of 1995, including statements that express the Company’s opinions, expectations, beliefs, plans, objectives, assumptions or projections regarding future events or future results, in contrast with statements that reflect historical facts. Examples include discussion of the Company’s research, pipeline and clinical trial plans. In some cases, you can identify such forward-looking statements by terminology such as “anticipate,” “intend,” “believe,” “estimate,” “plan,” “seek,” “project” or “expect,” “may,” “will,” “would,” “could” or “should,” the negative of these terms or similar expressions. Forward looking statements are based on management’s current beliefs and assumptions and on information currently available to the Company, and you should not place undue reliance on such statements. Forward-looking statements are subject to many risks and uncertainties, including the Company’s recurring losses from operations; the development of the Company’s product candidates, including statements regarding the timing of initiation, completion and the outcome of clinical studies or trials and related preparatory work and regulatory review; the Company’s ability to design and implement successful clinical trials for its product candidates; the potential for a pandemic, epidemic or outbreak of infectious diseases in the US, UK or EU, including the COVID-19 pandemic, to disrupt the Company’s clinical trial pipeline; the Company’s failure to demonstrate the safety and efficacy of its product candidates; the fact that results obtained in earlier stage clinical testing may not be indicative of results in future clinical trials; the Company’s ability to enroll patients in clinical trials for its product candidates; the possibility that one or more of the Company’s product candidates may cause serious adverse, undesirable or unacceptable side effects or have other properties that could delay or prevent their regulatory approval or limit their commercial potential; the Company’s ability to obtain and maintain regulatory approval of its product candidates; the Company’s limited manufacturing experience which could result in delays in the development, regulatory approval or commercialization of its product candidates; and the Company’s ability to identify or discover additional product candidates, or failure to capitalize on programs or product candidates. Such risks and uncertainties may cause the statements to be inaccurate and readers are cautioned not to place undue reliance on such statements. Many of these risks are outside of the Company’s control and could cause its actual results to differ materially from those it thought would occur. The forward-looking statements included in this press release are made only as of the date hereof. The Company does not undertake, and specifically declines, any obligation to update any such statements or to publicly announce the results of any revisions to any such statements to reflect future events or developments, except as required by law. For further information, please reference the Company’s reports and documents filed with the U.S. Securities and Exchange Commission. You may get these documents by visiting EDGAR on the SEC website at www.sec.gov.

Contact

David S. Arrington
Vice President Investor Relations & Corporate Communications
Freeline Therapeutics
[email protected]
+1 (646) 668 6947



Fate Therapeutics Announces Four Presentations at the 2021 ASGCT Annual Meeting

Two Oral Presentations to Cover iPSC-derived Cell-based Cancer Immunotherapy Pipeline

Company to Host Investor Event on May 13 to Highlight Interim Phase 1 Clinical Data from the Company’s FT516 and FT538 Programs for Relapsed / Refractory AML

SAN DIEGO, April 27, 2021 (GLOBE NEWSWIRE) — Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for patients with cancer, today announced that two oral and two digital presentations of the Company’s induced pluripotent stem cell (iPSC) product platform were accepted for presentation at the 24th American Society of Gene & Cell Therapy Annual Meeting (ASGCT) being held virtually from May 11-14, 2021.

In addition to the Company’s presentations at ASGCT, its iPSC-derived natural killer (NK) cell product pipeline is expected to be featured in a meeting symposium on May 11 by Jeffrey S. Miller, M.D., Professor of Medicine, University of Minnesota and Deputy Director of the Masonic Cancer Center and scientific advisor and collaborator of the Company, and its iPSC-derived CAR T-cell product platform is expected to be highlighted during the meeting’s plenary session on May 12 by Michel Sadelain, M.D., Ph.D., Stephen and Barbara Friedman Chair and Director, Center for Cell Engineering, Memorial Sloan Kettering Cancer Center and collaborator of the Company.

The Company also plans to host a virtual investor event on May 13 to highlight interim Phase 1 clinical data from its FT516 and FT538 programs for the treatment of relapsed / refractory acute myeloid leukemia (AML). The Phase 1 clinical trial of FT516 has enrolled the first and second dose cohorts (90 million and 300 million cells per dose, respectively), and dose escalation is ongoing in the third dose cohort (900 million cells per dose). The Phase 1 clinical trial of FT538 is ongoing in the first dose cohort (100 million cells per dose).

ASGCT Oral Presentations

  • Sequential CRISPR-mediated Engineering and Clonal Banking for the Generation of Multiplexed Engineered Master Pluripotent Cell Lines for the Mass Manufacture of Off-the-Shelf Immune Cells Targeting Solid Cancers

    Room 9 – Advances in Ex Vivo Modified Cell Therapies; Abstract 5; May 11, 2021; 6:30pm – 6:45pm EDT
  • Enhanced Generation of T-cell Derived Naïve Pluripotent Cells as a Renewable Cell Source for the Mass Manufacture of Off-the-shelf CAR T-cell Therapies

    Room 5 – CAR Modified Cellular Therapies; Abstract 76; May 12, 2021; 6:45pm – 7:00pm EDT

ASGCT Digital Presentations

  • Development and Application of a Pluripotent Stem Cell Platform to Generate Precision-Engineered Single Cell-derived Renewable Clonal Master Cell Lines for Therapeutic Use

    Abstract # 793
  • Temporal Gene Regulation of T-cell Enhancers by Locus Targeted Engineering Enables Cytokine Autonomy and Augments Anti-tumor Efficacy of iPSC-derived Off-the-shelf CAR-T Therapy

    Abstract #784

About Fate Therapeutics’ iPSC Product Platform

The Company’s proprietary induced pluripotent stem cell (iPSC) product platform enables mass production of off-the-shelf, engineered, homogeneous cell products that can be administered with multiple doses to deliver more effective pharmacologic activity, including in combination with other cancer treatments. Human iPSCs possess the unique dual properties of unlimited self-renewal and differentiation potential into all cell types of the body. The Company’s first-of-kind approach involves engineering human iPSCs in a one-time genetic modification event and selecting a single engineered iPSC for maintenance as a clonal master iPSC line. Analogous to master cell lines used to manufacture biopharmaceutical drug products such as monoclonal antibodies, clonal master iPSC lines are a renewable source for manufacturing cell therapy products which are well-defined and uniform in composition, can be mass produced at significant scale in a cost-effective manner, and can be delivered off-the-shelf for patient treatment. As a result, the Company’s platform is uniquely capable of overcoming numerous limitations associated with the production of cell therapies using patient- or donor-sourced cells, which is logistically complex and expensive and is subject to batch-to-batch and cell-to-cell variability that can affect clinical safety and efficacy. Fate Therapeutics’ iPSC product platform is supported by an intellectual property portfolio of over 350 issued patents and 150 pending patent applications.

About FT516
FT516 is an investigational, universal, off-the-shelf natural killer (NK) cell cancer immunotherapy derived from a clonal master induced pluripotent stem cell (iPSC) line engineered to express a novel high-affinity 158V, non-cleavable CD16 (hnCD16) Fc receptor, which has been modified to prevent its down-regulation and to enhance its binding to tumor-targeting antibodies. CD16 mediates antibody-dependent cellular cytotoxicity (ADCC), a potent anti-tumor mechanism by which NK cells recognize, bind and kill antibody-coated cancer cells. ADCC is dependent on NK cells maintaining stable and effective expression of CD16, which has been shown to undergo considerable down-regulation in cancer patients. In addition, CD16 occurs in two variants, 158V or 158F, that elicit high or low binding affinity, respectively, to the Fc domain of IgG1 antibodies. Numerous clinical studies with FDA-approved tumor-targeting antibodies, including rituximab, trastuzumab and cetuximab, have demonstrated that patients homozygous for the 158V variant, which is present in only about 15% of patients, have improved clinical outcomes. FT516 is being investigated in a multi-dose Phase 1 clinical trial as a monotherapy for the treatment of acute myeloid leukemia and in combination with CD20-targeted monoclonal antibodies for the treatment of advanced B-cell lymphoma (NCT04023071). Additionally, FT516 is being investigated in a multi-dose Phase 1 clinical trial in combination with avelumab for the treatment of advanced solid tumor resistant to anti-PDL1 checkpoint inhibitor therapy (NCT04551885).

About FT538

FT538 is an investigational, universal, off-the-shelf natural killer (NK) cell cancer immunotherapy derived from a clonal master induced pluripotent stem cell (iPSC) line engineered with three functional components: a novel high-affinity 158V, non-cleavable CD16 (hnCD16) Fc receptor, which has been modified to prevent its down-regulation and to enhance its binding to tumor-targeting antibodies; an IL-15 receptor fusion (IL-15RF) that augments NK cell activity; and the deletion of the CD38 gene (CD38KO), which promotes persistence and function in high oxidative stress environments. FT538 is designed to enhance innate immunity in cancer patients, where endogenous NK cells are typically diminished in both number and function due to prior treatment regimens and tumor suppressive mechanisms. In preclinical studies, FT538 has shown superior NK cell effector function, as compared to peripheral blood NK cells, with the potential to confer significant anti-tumor activity to patients through multiple mechanisms of action. FT538 is being investigated in a multi-dose Phase 1 clinical trial for the treatment of acute myeloid leukemia (AML) and in combination with daratumumab, a CD38-targeted monoclonal antibody therapy, for the treatment of multiple myeloma (NCT04614636).

About Fate Therapeutics, Inc.

Fate Therapeutics is a clinical-stage biopharmaceutical company dedicated to the development of first-in-class cellular immunotherapies for patients with cancer. The Company has established a leadership position in the clinical development and manufacture of universal, off-the-shelf cell products using its proprietary induced pluripotent stem cell (iPSC) product platform. The Company’s immuno-oncology pipeline includes off-the-shelf, iPSC-derived natural killer (NK) cell and T-cell product candidates, which are designed to synergize with well-established cancer therapies, including immune checkpoint inhibitors and monoclonal antibodies, and to target tumor-associated antigens using chimeric antigen receptors (CARs). The Company’s pipeline also includes ProTmune™, a pharmacologically modulated, donor cell graft that is currently being evaluated in a Phase 2 clinical trial for the prevention of graft-versus-host disease in patients with hematologic malignancies undergoing allogeneic stem cell transplant. Fate Therapeutics is headquartered in San Diego, CA. For more information, please visit www.fatetherapeutics.com.

Forward-Looking Statements

This release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 including statements regarding the Company’s clinical studies and preclinical research and development programs. These and any other forward-looking statements in this release are based on management’s current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to, the risk that results observed in prior studies of its product candidates, including preclinical studies and clinical trials of any of its product candidates, will not be observed in ongoing or future studies involving these product candidates, and the risk that the Company may cease or delay preclinical or clinical development of any of its product candidates for a variety of reasons (including requirements that may be imposed by regulatory authorities on the initiation or conduct of clinical trials or to support regulatory approval, difficulties or delays in subject enrollment in current and planned clinical trials, difficulties in manufacturing or supplying the Company’s product candidates for clinical testing, and any adverse events or other negative results that may be observed during preclinical or clinical development). For a discussion of other risks and uncertainties, and other important factors, any of which could cause the Company’s actual results to differ from those contained in the forward-looking statements, see the risks and uncertainties detailed in the Company’s periodic filings with the Securities and Exchange Commission, including but not limited to the Company’s most recently filed periodic report, and from time to time in the Company’s press releases and other investor communications. Fate Therapeutics is providing the information in this release as of this date and does not undertake any obligation to update any forward-looking statements contained in this release as a result of new information, future events or otherwise.

Contact:

Christina Tartaglia
Stern Investor Relations, Inc.
212.362.1200
[email protected]



Northeast Indiana Bancorp, Inc. Announces Cash Dividend And Holds Twenty-Sixth Annual Shareholder Meeting

PR Newswire

HUNTINGTON, Ind., April 27, 2021 /PRNewswire/ — Northeast Indiana Bancorp, Inc., (OTCQB:  NIDB), the parent company of First Federal Savings Bank, has announced that the Corporation will pay a cash dividend of $0.28 per common share.  The dividend will be payable on May 27, 2021 to shareholders of record on May 13, 2021.

Northeast Indiana Bancorp Inc. was named to the “Dividends Champions” list in 2020 by Dividendvaluebuilder.com.  This prestigious list recognizes public companies who have increased their cash dividend every year for twenty-five consecutive years or more.  Northeast Indiana Bancorp, Inc. is one of only eighteen banks to make the list out of approximately 880 public companies.  The complete list can be viewed at https://dividendvaluebuilder.com/dividend-champions-list/.

Northeast Indiana Bancorp, Inc. held its twenty-sixth annual shareholders’ meeting April 27, 2021.  The shareholders selected Michael S. Zahn and Kyle D. Koob as directors of the company for terms to expire in 2024.  

The book value of NIDB’s stock was $38.22 per common share as of March 31, 2021.  The last reported trade of stock at the close of business on April 26, 2021 was $42.10 per common share and the number of outstanding shares was 1,202,985 as of the same date.  The annualized dividend yield is currently 2.7% when annualizing the current quarter cash dividend of $0.28 per common share against the April 27, 2021 closing price of $42.10 per common share. 

Northeast Indiana Bancorp, Inc. is headquartered at 648 N. Jefferson Street, Huntington, Indiana.  The company offers a full array of banking and financial brokerage services to its customers through its main office in Huntington and five full-service Indiana offices in Huntington (2), Warsaw and Fort Wayne(2).  The Company is traded on the OTC Markets Group, Inc. (www.otcmarkets.com) utilizing the OTCQB platform under the symbol “NIDB”.  Our web site address is www.firstfedindiana.bank.

 

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/northeast-indiana-bancorp-inc-announces-cash-dividend-and-holds-twenty-sixth-annual-shareholder-meeting-301278412.html

SOURCE Northeast Indiana Bancorp, Inc.

WesBanco Announces First Quarter 2021 Financial Results

PR Newswire

WHEELING, W.Va., April 27, 2021 /PRNewswire/ — WesBanco, Inc. (“WesBanco”) (Nasdaq: WSBC), a diversified, multi-state bank holding company, today announced net income and related earnings per share for the three months ended March 31, 2021.  Net income available to common shareholders for the period was $70.6 million, with diluted earnings per share of $1.05, compared to $23.4 million and $0.35 per diluted share, respectively, for the first quarter of 2020.  Net income available to common shareholders excluding after-tax restructuring and merger-related expenses for the three months ended March 31, 2021, was $71.3 million, or $1.06 per diluted share, as compared to $27.5 million and $0.41 per diluted share, respectively, in the prior year quarter (non-GAAP measures).



For the Three Months Ended March 31,



2021



2020


(unaudited, dollars in thousands,
except per share amounts)



Net Income



Diluted
Earnings
Per Share




Net Income



Diluted
Earnings
Per Share


Net income available to common
shareholders (Non-GAAP)(1)

$      71,256

$       1.06

$      27,476

$       0.41

Less: After-tax restructuring and merger-
related expenses

(672)

(0.01)

(4,080)

(0.06)

Net income available to common
shareholders (GAAP)

$      70,584

$       1.05

$      23,396

$       0.35


(1)See non-GAAP financial measures for additional information relating to the calculation of these items.

WesBanco believes that pre-tax, pre-provision income (non-GAAP measure) provides a more comparable year-over-year measure as it removes the provision for credit losses to improve comparability from quarter-to-quarter due to the CECL accounting standard.  For the three months ended March 31, 2021, pre-tax, pre-provision income, excluding restructuring and merger-related expenses, increased 3.6% year-over-year to $64.2 million compared to $62.0 million for the prior period.  In addition, on the same basis, the return on average assets was 1.57% for the three month period ending March 31, 2021.  WesBanco believes that these non-GAAP financial measures are useful to investors as they enhance investors’ understanding of the Company’s business and performance.

Financial and operational highlights during the quarter ended March 31, 2021:

  • Strong year-over-year growth in pre-tax, pre-provision income (non-GAAP measure)
  • Continued expense management demonstrated by a year-to-date efficiency ratio of 56.71% (non-GAAP measure)
  • Improving macro-economic factors utilized in the CECL calculation drove both the net benefit in the provision for credit losses and the reduction in allowance for credit losses during the quarter
  • Key credit quality metrics such as non-performing assets, past due loans, and net loan charge-offs, as percentages of total portfolio loans, have remained at low levels and favorable to peer bank averages, those with total assets between $10 billion and $25 billion (based upon the prior four quarters)
  • Total loan growth was 3.4% year-over-year, driven by WesBanco’s support of businesses impacted by the pandemic through the Small Business Administration’s Payroll Protection Program (“SBA PPP”)
  • Deposit growth, excluding certificates of deposit, was 28.9% year-over-year, driven by growth in demand deposits
  • Trust assets under management totaled a record $5.2 billion, driven by both market appreciation and organic growth
  • WesBanco is a well-capitalized financial institution with solid liquidity and a strong balance sheet
  • On April 22, 2021, WesBanco’s Board of Directors authorized the adoption of a new stock repurchase program, which, when combined with the remainder of the previous authorization, represents approximately 5% of outstanding shares

“We are pleased with WesBanco’s performance during the first quarter of 2021 as we are in the early stages of emerging from the pandemic,” said Todd F. Clossin, President and Chief Executive Officer of WesBanco.  “I am proud of our entire organization as it has worked tirelessly to serve our customers and communities throughout the past year.  Their outstanding efforts led to WesBanco Bank recently being named, for the third year in a row, one of the world’s best banks in an independent ranking based solely on customer satisfaction and feedback.  This exceptional ranking is in addition to being named one of the fifteen best banks in America by Forbes magazine, which represents our eleventh year making the list since its inception in 2010.”

Mr. Clossin added, “I would also like to recognize Abdul Muhammad, our Senior Vice President and Regional Manager of Residential Lending.  In addition to his chairing our Diversity, Equity, and Inclusion Council, he was recently appointed as one of the eight members of the Federal Reserve Bank of Cleveland’s Equity and Inclusion Advisory Council.  We are excited about our opportunities for the upcoming year as we build upon our well-defined, long-term strategies by leveraging the efforts of Abdul and our Council to further the principles of diversity and inclusion across not just WesBanco but also our communities.”


Balance Sheet

Portfolio loans of $10.7 billion as of March 31, 2021 increased 3.4% when compared to the prior year period, due primarily to participation in the SBA PPP, which totaled approximately 7,750 loans for $824 million.  During the first quarter, approximately 2,330 customers applied for and received forgiveness of their Round 1 SBA PPP loans totaling $223 million; while our lenders assisted more than 3,240 businesses with Round 2 SBA PPP loans totaling approximately $344 million.

Total deposits increased 20.3% year-over-year to $13.3 billion due primarily to CARES Act stimulus funds received and increased personal savings, which more than offset a $384.2 million reduction in certificates of deposit.  Deposits, excluding CDs, increased 28.9% year-over-year, driven by a 36.0% increase in total demand deposits, which represent approximately 57% of total deposits.


Credit Quality

As of March 31, 2021, total loans past due, non-performing loans, and non-performing assets as percentages of the portfolio and total assets have remained relatively low and consistent throughout the last five quarters.  Furthermore, on a sequential quarter-basis as compared to the quarter ending December 31, 2020, total loans past due declined $7.0 million, total non-performing assets decreased $2.8 million, and total criticized and classified loans declined $39.0 million.  In addition, annualized net loan charge-offs to average loans remained low for the quarter at two basis points.  Reflecting improved macroeconomic factors in the CECL calculation, the allowance for credit losses specific to total portfolio loans at March 31, 2021 was $160.0 million, or 1.50% of total loans; or, when excluding SBA PPP loans, 1.62% of total portfolio loans.  Excluded from the allowance for credit losses and related coverage ratio are fair market value adjustments on previously acquired loans representing 0.34% of total loans.  The improved factors resulted in a negative provision for credit losses of $28.0 million for the first quarter of 2021.


Net Interest Margin and Income

The net interest margin of 3.27% for the first quarter of 2021 decreased four and 27 basis points, respectively, from the fourth and first quarters of 2020, primarily due to the lower interest rate environment.  As a result of higher cash balances from additional stimulus funds received by our customers and their higher personal savings creating extra liquidity, investment securities increased by $0.9 billion during the first quarter, mostly during March.  Reflecting the significantly lower interest rate environment, we aggressively reduced our deposit rates throughout the past year, which helped to lower deposit funding costs 35 basis points year-over-year to 20 basis points for the first quarter of 2021, or 14 basis points when including non-interest bearing deposits.  Further, we lowered the cost of FHLB borrowings 25 basis points year-over-year as we reduced first quarter average borrowings by $1.0 billion, or 66.8%, year-over-year to $0.5 billion, which have a remaining average life of less than one year.  Accretion from acquisitions benefited the first quarter net interest margin by 13 basis points, as compared to 22 basis points in the prior year period and 16 basis points during the fourth quarter of 2020.  Lastly, the forgiveness of existing and funding of new SBA PPP loans benefited the first quarter of 2021 net interest margin by a net 11 basis points, and will positively impact the net interest margin as the loans are forgiven during the next couple of quarters.

Net interest income decreased $3.7 million, or 3.1%, during the first quarter of 2021, as compared to the same quarter of 2020, reflecting lower loan yields due to repricing of existing loans and lower new offered rates in the current market environment, lower related accretion from purchase accounting, and lower rates on investment securities partially offset by lower interest on depostis and borrowings as described above.


Non-Interest Income

For the first quarter of 2021, non-interest income of $33.2 million increased $5.2 million, or 18.6%, from the first quarter of 2020, driven primarily by mortgage banking income and higher commercial customer loan swap-related income, which were partially offset by lower service charges on deposits and net securities gains.  Reflecting the low interest rate environment and organic growth, mortgage banking fees increased $3.0 million, or 234.2%, compared to the prior year period, net of fair value adjustments, as residential mortgage origination dollar volume increased approximately 50% year-over-year, with roughly 60% of those originations sold into the secondary market.  Loan swap-related income was $4.7 million, an increase of $4.8 million year-over-year, primarily the result of $2.8 million of fair market value adjustments in the current period as compared to a negative $2.8 million adjustment last year.  Service charges on deposits were lower due to higher consumer deposits associated with the three rounds of stimulus to-date and lower general consumer spending, resulting in fewer eligible account fees.

WesBanco has jointly executed a purchase agreement in which Pueblo Bank and Trust (“PB&T”) will acquire WesBanco’s non-essential debit card sponsorship portfolio of clients, which was acquired as part of its Old Line Bancshares, Inc. merger.  The all-cash purchase price is for a maximum of $2.8 million, which will be paid monthly over a two-year period based on a 50%-50% split of the monthly gross revenue earned by PB&T.


Non-Interest Expense

Total operating expenses continued to be well-controlled through company-wide efforts to effectively manage discretionary costs and full-time equivalent employee counts, as demonstrated by a year-to-date efficiency ratio of 56.71%.  Excluding restructuring and merger-related expenses, non-interest expense for the three months ended March 31, 2021 decreased $0.7 million, or 0.8%, to $85.5 million compared to the prior year period, primarily due to lower salaries and wages from the recent financial center closures, as well as continuing cost control measures over certain discretionary expenses.  Marketing expense for the first quarter of 2021 increased $1.2 million, or 109.5%, year-over-year due to increased product advertising and brand awareness campaigns that were delayed from 2020 due to the COVID-19 pandemic.


Capital

WesBanco continues to maintain what we believe are strong regulatory capital ratios, as both consolidated and bank-level regulatory capital ratios are well above the applicable “well-capitalized” standards promulgated by bank regulators and the BASEL III capital standards.  At March 31, 2021, Tier I leverage was 10.74%, Tier I risk-based capital ratio was 14.95%, common equity Tier 1 capital ratio (“CET 1”) was 13.65%, and total risk-based capital was 17.58%.

On April 22, 2021, WesBanco’s Board of Directors authorized the adoption of a new stock repurchase plan for the purchase of up to an additional 1.7 million shares of WesBanco common stock from time to time on the open market.  This new stock repurchase authorization is in addition to the existing stock repurchase program approved by WesBanco’s Board of Directors on December 19, 2019 which has approximately 1.7 million shares remaining for repurchase and will continue to be utilized until such authorization is completed.  The combination of these two authorizations represents approximately 5.0% of outstanding shares.


Conference Call and Webcast

WesBanco will host a conference call to discuss the Company’s financial results for the first quarter of 2021 at 10:00 a.m. ET on Wednesday, April 28, 2021.  Interested parties can access the live webcast of the conference call through the Investor Relations section of the Company’s website, www.wesbanco.com.  Participants can also listen to the conference call by dialing 888-347-6607, 855-669-9657 for Canadian callers, or 412-902-4290 for international callers, and asking to be joined into the WesBanco call.

A replay of the conference call will be available by dialing 877-344-7529, 855-669-9658 for Canadian callers, or 412-317-0088 for international callers, and providing the access code of 10150967.  The replay will begin at approximately 12:00 p.m. ET on April 28, and end at 12 a.m. ET on May 12.  An archive of the webcast will be available for one year on the Investor Relations section of the Company’s website (www.wesbanco.com).


Forward-Looking Statements

Forward-looking statements in this report relating to WesBanco’s plans, strategies, objectives, expectations, intentions and adequacy of resources, are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.  The information contained in this report should be read in conjunction with WesBanco’s Form 10-K for the year ended December 31, 2020 and documents subsequently filed by WesBanco with the Securities and Exchange Commission (“SEC”), which are available at the SEC’s website, www.sec.gov or at WesBanco’s website, www.WesBanco.com.  Investors are cautioned that forward-looking statements, which are not historical fact, involve risks and uncertainties, including those detailed in WesBanco’s most recent Annual Report on Form 10-K filed with the SEC under “Risk Factors” in Part I, Item 1A.  Such statements are subject to important factors that could cause actual results to differ materially from those contemplated by such statements, including, without limitation, the effects of changing regional and national economic conditions including the effects of the COVID-19 pandemic; changes in interest rates, spreads on earning assets and interest-bearing liabilities, and associated interest rate sensitivity; sources of liquidity available to WesBanco and its related subsidiary operations; potential future credit losses and the credit risk of commercial, real estate, and consumer loan customers and their borrowing activities; actions of the Federal Reserve Board, the Federal Deposit Insurance Corporation, the SEC, the Financial Institution Regulatory Authority, the Municipal Securities Rulemaking Board, the Securities Investors Protection Corporation, and other regulatory bodies; potential legislative and federal and state regulatory actions and reform, including, without limitation, the impact of the implementation of the Dodd-Frank Act; adverse decisions of federal and state courts; fraud, scams and schemes of third parties; cyber-security breaches; competitive conditions in the financial services industry; rapidly changing technology affecting financial services; marketability of debt instruments and corresponding impact on fair value adjustments; and/or other external developments materially impacting WesBanco’s operational and financial performance.  WesBanco does not assume any duty to update forward-looking statements.


Non-GAAP Financial Measures

In addition to the results of operations presented in accordance with Generally Accepted Accounting Principles (GAAP), WesBanco’s management uses, and this presentation contains or references, certain non-GAAP financial measures, such as pre-tax pre-provision income, tangible common equity/tangible assets; net income excluding after-tax restructuring and merger-related expenses; efficiency ratio; return on average assets; and return on average tangible equity.  WesBanco believes these financial measures provide information useful to investors in understanding our operational performance and business and performance trends which facilitate comparisons with the performance of others in the financial services industry. Although WesBanco believes that these non-GAAP financial measures enhance investors’ understanding of WesBanco’s business and performance, these non-GAAP financial measures should not be considered an alternative to GAAP. The non-GAAP financial measures contained therein should be read in conjunction with the audited financial statements and analysis as presented in the Annual Report on Form 10-K as well as the unaudited financial statements and analyses as presented in the Quarterly Reports on Forms 10-Q for WesBanco and its subsidiaries, as well as other filings that the company has made with the SEC.


About WesBanco, Inc.

Founded in 1870, WesBanco, Inc. (www.wesbanco.com) is a diversified and balanced financial services company that delivers large bank capabilities with a community bank feel.  Our distinct long-term growth strategies are built upon unique sustainable advantages permitting us to span six states with meaningful market share.  Built upon our ‘Better Banking Pledge’, our customer-centric service culture is focused on growing long-term relationships by pledging to serve all personal and business customer needs efficiently and effectively.  In addition to a full range of online and mobile banking options and a full-suite of commercial products and services, WesBanco provides trust, wealth management, securities brokerage, and private banking services through our century-old Trust and Investment Services department, with approximately $5.2 billion of assets under management (as of March 31, 2021).  WesBanco’s banking subsidiary, WesBanco Bank, Inc., operates 212 financial centers in the states of Indiana, Kentucky, Maryland, Ohio, Pennsylvania, and West Virginia.  Additionally, WesBanco operates an insurance agency, WesBanco Insurance Services, Inc., and a full service broker/dealer, WesBanco Securities, Inc.

 


WESBANCO, INC.


Consolidated Selected Financial Highlights


Page 5


(unaudited, dollars in thousands, except shares and per share amounts)



For the Three Months Ended



STATEMENT OF INCOME



March 31,


Interest and dividend income



2021



2020



% Change

Loans, including fees


$          109,358

$             119,503

(8.5)

Interest and dividends on securities:

Taxable 


11,127

16,986

(34.5)

Tax-exempt


3,910

4,456

(12.3)

Total interest and dividends on securities


15,037

21,442

(29.9)

Other interest income 


659

1,503

(56.2)

          Total interest and dividend income


125,054

142,448

(12.2)


Interest expense

Interest bearing demand deposits


1,043

3,394

(69.3)

Money market deposits


578

2,352

(75.4)

Savings deposits


264

923

(71.4)

Certificates of deposit


2,370

4,054

(41.5)

Total interest expense on deposits


4,255

10,723

(60.3)

Federal Home Loan Bank borrowings


2,414

8,232

(70.7)

Other short-term borrowings


118

870

(86.4)

Subordinated debt and junior subordinated debt 


1,789

2,461

(27.3)

Total interest expense


8,576

22,286

(61.5)


Net interest income 


116,478

120,162

(3.1)

Provision for credit losses


(27,958)

29,821

(193.8)

Net interest income after provision for credit losses


144,436

90,341

59.9


Non-interest income

Trust fees


7,631

6,952

9.8

Service charges on deposits


4,894

6,617

(26.0)

Electronic banking fees


4,365

4,254

2.6

Net securities brokerage revenue


1,524

1,679

(9.2)

Bank-owned life insurance


1,709

1,769

(3.4)

Mortgage banking income


4,264

1,276

234.2

Net securities gains


279

1,491

(81.3)

Net gain on other real estate owned and other assets


175

169

3.6

Other income


8,367

3,802

120.1

Total non-interest income


33,208

28,009

18.6


Non-interest expense

Salaries and wages


36,890

38,910

(5.2)

Employee benefits


10,266

10,373

(1.0)

Net occupancy


7,177

7,084

1.3

Equipment and software


6,765

6,039

12.0

Marketing


2,384

1,138

109.5

FDIC insurance 


1,282

2,113

(39.3)

Amortization of intangible assets


2,896

3,374

(14.2)

Restructuring and merger-related expense


851

5,164

(83.5)

Other operating expenses  


17,816

17,138

4.0

Total non-interest expense


86,327

91,333

(5.5)

Income before provision for income taxes


91,317

27,017

238.0

Provision for income taxes 


18,202

3,621

402.7

Net Income


73,115

23,396

212.5

Preferred stock dividends


2,531

100.0


Net income available to common shareholders


$             70,584

$               23,396

201.7


Taxable equivalent net interest income



$          117,517


$          121,346

(3.2)



Per common share data

Net income per common share – basic


$                 1.05

$                   0.35

200.0

Net income per common share – diluted


1.05

0.35

200.0

Net income per common share – diluted, excluding certain items (1)(2)


1.06

0.41

158.5

Dividends declared


0.33

0.32

3.1

Book value (period end)


39.25

38.56

1.8

Tangible book value (period end) (1)


22.21

21.36

4.0

Average common shares outstanding – basic


67,263,714

67,486,550

(0.3)

Average common shares outstanding – diluted


67,355,418

67,587,446

(0.3)

Period end common shares outstanding


67,282,134

67,058,155

0.3

Period end preferred shares outstanding


150,000

100.0


(1) See non-GAAP financial measures for additional information relating to the calculation of this item.


(2) Certain items excluded from the calculation consist of after-tax restructuring and merger-related expenses.

 


WESBANCO, INC.


Consolidated Selected Financial Highlights


Page 6


(unaudited, dollars in thousands)



Selected ratios



For the Three Months Ended



March 31,



2021



2020



% Change

Return on average assets


1.72


%

0.60

%

186.67

%

Return on average assets, excluding

    after-tax restructuring and merger-related expenses (1)


1.74

0.70

148.57

Return on average equity


10.33

3.63

184.57

Return on average equity, excluding

    after-tax restructuring and merger-related expenses (1)

10.43

4.26

144.84

Return on average tangible equity (1)


18.22

7.07

157.71

Return on average tangible equity, excluding 

    after-tax restructuring and merger-related expenses (1)


18.39

8.18

124.82

Return on average tangible common equity (1)


20.00

7.07

182.89

Return on average tangible common equity, excluding 

    after-tax restructuring and merger-related expenses (1)


20.18

8.18

146.70

Yield on earning assets (2) 


3.51

4.19

(16.23)

Cost of interest bearing liabilities


0.37

0.91

(59.34)

Net interest spread (2)


3.14

3.28

(4.27)

Net interest margin (2)


3.27

3.54

(7.63)

Efficiency (1) (2)


56.71

57.69

(1.70)

Average loans to average deposits


85.27

94.61

(9.87)

Annualized net loan charge-offs/average loans


0.02

0.18

(88.89)

Effective income tax rate 


19.93

13.40

48.73



For the Quarter Ended



Mar. 31,



Dec. 31,



Sept. 30,



June 30,



Mar. 31,



2021



2020



2020



2020



2020

Return on average assets


1.72


%

1.21


%

0.98

%

0.11

%

0.60

%

Return on average assets, excluding

    after-tax restructuring and merger-related expenses (1)


1.74

1.22

1.05

0.12

0.70

Return on average equity


10.33

7.28

6.17

0.69

3.63

Return on average equity, excluding

    after-tax restructuring and merger-related expenses (1)


10.43

7.33

6.60

0.75

4.26

Return on average tangible equity (1)


18.22

13.18

11.56

1.98

7.07

Return on average tangible equity, excluding 

    after-tax restructuring and merger-related expenses (1)


18.39

13.28

12.31

2.08

8.18

Return on average tangible common equity (1)


20.00

14.49

12.21

1.98

7.07

Return on average tangible common equity, excluding 

.

    after-tax restructuring and merger-related expenses (1)


20.18

14.60

13.00

2.08

8.18

Yield on earning assets (2) 


3.51

3.61

3.66

3.75

4.19

Cost of interest bearing liabilities


0.37

0.45

0.53

0.63

0.91

Net interest spread (2)


3.14

3.16

3.13

3.12

3.28

Net interest margin (2)


3.27

3.31

3.31

3.32

3.54

Efficiency (1) (2) 


56.71

57.06

55.23

55.57

57.69

Average loans to average deposits


85.27

89.64

90.88

91.87

94.61

Annualized net loan charge-offs and recoveries /average loans


0.02

0.02

(0.00)

0.07

0.18

Effective income tax rate 


19.93

18.13

15.66

0.93

13.40

Trust assets, market value at period end


$           5,244,370

$              5,025,565

$              4,649,054

$              4,487,042

$              4,082,141


(1) See non-GAAP financial measures for additional information relating to the calculation of this item.


(2) The yield on earning assets, net interest margin, net interest spread and efficiency ratios are presented on a fully 


    taxable-equivalent (FTE) and annualized basis. The FTE basis adjusts for the tax benefit of income on certain tax-exempt 


   loans and investments.   WesBanco believes this measure to be the preferred industry measurement of net interest income and


   provides a relevant comparison between taxable and non-taxable amounts.

 


WESBANCO, INC.


Consolidated Selected Financial Highlights


Page 7


(unaudited, dollars in thousands, except shares)


% Change



Balance sheets



March 31,



December 31,


December 31, 2020


Assets



2021



2020


% Change



2020


to March 31, 2021

Cash and due from banks

$           209,040

$           183,138

14.1

$           184,361

13.4

Due from banks – interest bearing

550,008

410,734

33.9

721,086

(23.7)

Securities:

Equity securities, at fair value

13,123

11,230

16.9

13,047

0.6

Available-for-sale debt securities, at fair value

2,775,212

2,262,082

22.7

1,978,136

40.3

Held-to-maturity debt securities (fair values of $839,872; $841,120 

and $768,183, respectively)

813,740

814,414

(0.1)

731,212

11.3

Allowance for credit losses, held-to-maturity debt securities

(290)

(236)

(22.9)

(326)

11.0

Net held-to-maturity debt securities

813,450

814,178

(0.1)

730,886

11.3

Total securities

3,601,785

3,087,490

16.7

2,722,069

32.3

Loans held for sale

153,520

48,021

219.7

168,378

(8.8)

Portfolio loans:

Commercial real estate

5,712,742

5,604,405

1.9

5,705,392

0.1

Commercial and industrial

2,422,735

1,801,751

34.5

2,407,438

0.6

Residential real estate 

1,644,422

1,929,590

(14.8)

1,720,961

(4.4)

Home equity

634,018

650,754

(2.6)

646,387

(1.9)

Consumer 

289,395

363,096

(20.3)

309,055

(6.4)

Total portfolio loans, net of unearned income

10,703,312

10,349,596

3.4

10,789,233

(0.8)

Allowance for credit losses – loans

(160,040)

(114,272)

(40.1)

(185,827)

13.9

Net portfolio loans

10,543,272

10,235,324

3.0

10,603,406

(0.6)

Premises and equipment, net

239,863

258,200

(7.1)

249,421

(3.8)

Accrued interest receivable

68,896

43,960

56.7

66,790

3.2

Goodwill and other intangible assets, net

1,160,195

1,170,070

(0.8)

1,163,091

(0.2)

Bank-owned life insurance

307,747

301,270

2.1

306,038

0.6

Other assets

223,462

257,365

(13.2)

240,970

(7.3)


Total Assets


$   17,057,788


$   15,995,572


6.6


$   16,425,610


3.8


Liabilities

Deposits:

Non-interest bearing demand

$        4,460,049

$        3,191,713

39.7

$        4,070,835

9.6

Interest bearing demand

3,126,186

2,388,406

30.9

2,839,536

10.1

Money market

1,771,703

1,539,835

15.1

1,685,927

5.1

Savings deposits

2,373,987

1,984,057

19.7

2,214,565

7.2

Certificates of deposit

1,555,074

1,939,321

(19.8)

1,618,510

(3.9)

Total deposits

13,286,999

11,043,332

20.3

12,429,373

6.9

Federal Home Loan Bank borrowings

433,984

1,585,608

(72.6)

549,003

(21.0)

Other short-term borrowings

137,218

333,966

(58.9)

241,950

(43.3)

Subordinated debt and junior subordinated debt 

192,430

192,008

0.2

192,291

0.1

Total borrowings

763,632

2,111,582

(63.8)

983,244

(22.3)

Accrued interest payable

3,224

7,667

(57.9)

4,314

(25.3)

Other liabilities

218,411

246,931

(11.5)

251,942

(13.3)


Total Liabilities

14,272,266

13,409,512

6.4

13,668,873

4.4


Shareholders’ Equity

Preferred stock, no par value; 1,000,000 shares authorized in 2021 and 2020, respectively; 

150,000 shares 6.75% non-cumulative perpetual preferred stock, Series A, 

liquidation preference $150.0 million, issued and outstanding at March 31, 2021 and 

December 31, 2020 and 0 shares issued and outstanding at March 31, 2020, respectively

144,484

100.0

144,484

Common stock, $2.0833 par value; 100,000,000 shares authorized in

2021 and 2020, respectively; 68,081,306, 68,078,116 and 68,081,306 shares

issued, respectively; 67,282,134, 67,058,155 and 67,254,706 shares

141,834

141,827

0.0

141,834

outstanding, respectively

Capital surplus

1,636,103

1,638,122

(0.1)

1,634,815

0.1

Retained earnings

879,786

800,064

10.0

831,688

5.8

Treasury stock (799,172, 1,019,961 and 826,600 shares – at cost, respectively)

(24,989)

(33,714)

25.9

(25,949)

3.7

Accumulated other comprehensive income

9,803

41,141

(76.2)

31,359

(68.7)

Deferred benefits for directors

(1,499)

(1,380)

(8.6)

(1,494)

(0.3)


Total Shareholders’ Equity

2,785,522

2,586,060

7.7

2,756,737

1.0


Total Liabilities and Shareholders’ Equity


$   17,057,788


$   15,995,572


6.6


$   16,425,610


3.8

 


WESBANCO, INC.


Consolidated Selected Financial Highlights


Page 8


(unaudited, dollars in thousands)



Average balance sheet and



net interest margin analysis


For the Three Months Ended March 31,



2021



2020



Average 



Average



Average 



Average


Assets



Balance



Rate



Balance



Rate

Due from banks – interest bearing

$                 776,245

0.09

%

$                 133,532

1.21

%

Loans, net of unearned income (1)

10,890,370

4.07

10,375,187

4.63

Securities: (2)

    Taxable

2,306,320

1.96

2,576,668

2.65

    Tax-exempt (3)

580,199

3.46

646,587

3.51

        Total securities

2,886,519

2.26

3,223,255

2.82

Other earning assets 

33,240

5.89

69,581

6.37


         Total earning assets (3)


14,586,374


3.51


%


13,801,555


4.19


%

Other assets

2,049,884

1,983,384


Total Assets


$         16,636,258


$         15,784,939


Liabilities and Shareholders’ Equity

Interest bearing demand deposits

$              2,970,766

0.14

%

$              2,342,441

0.58

%

Money market accounts 

1,725,561

0.14

1,543,763

0.61

Savings deposits

2,290,657

0.05

1,953,487

0.19

Certificates of deposit

1,584,152

0.61

1,989,450

0.82

    Total interest bearing deposits

8,571,136

0.20

7,829,141

0.55

Federal Home Loan Bank borrowings

488,388

2.00

1,471,175

2.25

Other borrowings

191,676

0.25

336,042

1.04

Subordinated debt and junior subordinated debt 

192,341

3.77

198,494

4.99


      Total interest bearing liabilities (4)


9,443,541


0.37


%


9,834,852


0.91


%

Non-interest bearing demand deposits

4,200,793

3,137,279

Other liabilities

221,508

218,739

Shareholders’ equity

2,770,416

2,594,069


Total Liabilities and Shareholders’ Equity


$         16,636,258


$         15,784,939


Taxable equivalent net interest spread


3.14


%


3.28


%


Taxable equivalent net interest margin 


3.27


%


3.54


%

(1) Gross of allowance for loan losses and net of unearned income.  Includes non-accrual and loans held for sale. Loan fees included in interest income on loans were $8.2 million and $0.7 million for
the three months ended March 31, 2021 and 2020, respectively. PPP loan fees, which are included as part of total loan fees, were $7.9 million for the three months ended March 31, 2021. 
Additionally, loan accretion included in interest income on loans acquired from prior acquisitions was $3.5 million and $4.1 million for the three months ended March 31, 2021 and 2020, respectively. 

(2) Average yields on available-for-sale securities are calculated based on amortized cost.

(3) Taxable equivalent basis is calculated on tax-exempt securities using a federal statutory rate of 21% for each period presented.

(4) Accretion on interest bearing liabilities acquired from the prior acquisitions was $1.1 million and $3.4 million for the three months ended March 31, 2021 and 2020, respectively.

 


WESBANCO, INC.


Consolidated Selected Financial Highlights


 Page 9 


(unaudited, dollars in thousands, except shares and per share amounts)



Quarter Ended



Statement of Income



Mar. 31,


Dec. 31,


Sept.  30,


June 30,


Mar. 31,


Interest and dividend income



2021


2020


2020


2020


2020

Loans, including fees


$                   109,358

$              114,582

$            116,524

$              115,068

$            119,503

Interest and dividends on securities:

Taxable 


11,127

10,892

11,669

14,047

16,986

Tax-exempt


3,910

4,059

4,182

4,302

4,456

Total interest and dividends on securities


15,037

14,951

15,851

18,349

21,442

Other interest income 


659

945

1,282

1,277

1,503

          Total interest and dividend income


125,054

130,478

133,657

134,694

142,448


Interest expense

Interest bearing demand deposits


1,043

1,099

1,225

1,350

3,394

Money market deposits


578

678

707

879

2,352

Savings deposits


264

280

303

297

923

Certificates of deposit


2,370

2,797

3,197

3,514

4,054

Total interest expense on deposits


4,255

4,854

5,432

6,040

10,723

Federal Home Loan Bank borrowings


2,414

3,719

5,457

7,293

8,232

Other short-term borrowings


118

275

304

279

870

Subordinated debt and junior subordinated debt


1,789

1,918

1,871

2,069

2,461

Total interest expense


8,576

10,766

13,064

15,681

22,286


Net interest income 


116,478

119,712

120,593

119,013

120,162

Provision for credit losses


(27,958)

(209)

16,288

61,841

29,821

Net interest income after provision for credit losses


144,436

119,921

104,305

57,172

90,341


Non-interest income

Trust fees


7,631

6,754

6,426

6,202

6,952

Service charges on deposits


4,894

5,671

5,332

4,323

6,617

Electronic banking fees


4,365

4,424

4,780

4,066

4,254

Net securities brokerage revenue


1,524

1,402

1,725

1,384

1,679

Bank-owned life insurance


1,709

1,750

2,088

1,752

1,769

Mortgage banking income


4,264

5,442

8,488

7,531

1,276

Net securities gains


279

691

787

1,299

1,491

Net gain / (loss) on other real estate owned and other assets


175

18

(19)

(66)

169

Other income


8,367

6,553

5,005

6,369

3,802

Total non-interest income


33,208

32,705

34,612

32,860

28,009


Non-interest expense

Salaries and wages


36,890

39,140

38,342

36,773

38,910

Employee benefits


10,266

10,608

10,604

10,138

10,373

Net occupancy


7,177

6,771

7,092

6,634

7,084

Equipment and software


6,765

6,810

6,229

5,722

6,039

Marketing


2,384

1,675

1,577

1,567

1,138

FDIC insurance 


1,282

1,278

1,948

2,395

2,113

Amortization of intangible assets


2,896

3,327

3,346

3,365

3,374

Restructuring and merger-related expense


851

484

3,608

468

5,164

Other operating expenses  


17,816

17,976

17,198

18,440

17,138

Total non-interest expense


86,327

88,069

89,943

85,502

91,333

Income before provision for income taxes


91,317

64,557

48,974

4,530

27,017

Provision for income taxes 


18,202

11,703

7,669

42

3,621

Net Income


73,115

52,854

41,305

4,488

23,396

Preferred stock dividends


2,531

2,644


Net income available to common shareholders


$                      70,584

$                50,210

$              41,305

$                  4,488

$              23,396


Taxable equivalent net interest income



$                   117,517

$              120,790


$         121,705


$           120,156


$         121,346



Per common share data

Net income per common share – basic


$                          1.05

$                    0.75

$                  0.61

$                    0.07

$                  0.35

Net income per common share – diluted


1.05

0.75

0.61

0.07

0.35

Net income per common share – diluted, excluding certain items (1)(2)


1.06

0.76

0.66

0.07

0.41

Dividends declared


0.33

0.32

0.32

0.32

0.32

Book value (period end)


39.25

38.84

38.51

38.23

38.56

Tangible book value (period end) (1)


22.21

21.75

21.39

21.10

21.36

Average common shares outstanding – basic


67,263,714

67,238,005

67,214,759

67,104,828

67,486,550

Average common shares outstanding – diluted


67,355,418

67,304,442

67,269,303

67,181,756

67,587,446

Period end common shares outstanding


67,282,134

67,254,706

67,216,012

67,211,192

67,058,155

Period end preferred shares outstanding


150,000

150,000

150,000

Full time equivalent employees


2,490

2,612

2,618

2,676

2,703


(1) See non-GAAP financial measures for additional information relating to the calculation of this item.


(2) Certain items excluded from the calculation consist of after-tax restructuring and merger-related expenses.

 


WESBANCO, INC.


Consolidated Selected Financial Highlights


 Page 10 


(unaudited, dollars in thousands)



Quarter Ended



Mar. 31,



Dec. 31,



Sept. 30,



June 30,



Mar. 31,



Asset quality data



2021



2020



2020



2020



2020

Non-performing assets:

Troubled debt restructurings – accruing


$         3,563

$           3,927

$           4,191

$           5,105

$           5,434

Non-accrual loans:

Troubled debt restructurings


1,768

1,828

1,818

1,339

1,571

Other non-accrual loans


32,807

35,052

35,448

34,119

32,796

    Total non-accrual loans


34,575

36,880

37,266

35,458

34,367

    Total non-performing loans 


38,138

40,807

41,457

40,563

39,801

Other real estate and repossessed assets


393

549

738

1,212

1,083

Total non-performing assets


$       38,531

$         41,356

$         42,195

$         41,775

$         40,884

Past due loans (1):

Loans past due 30-89 days


$       20,602

$         31,596

$         17,338

$         30,595

$         32,805

Loans past due 90 days or more


12,824

8,846

10,170

36,903

14,287

Total past due loans


$       33,426

$         40,442

$         27,508

$         67,498

$         47,092

Criticized and classified loans (2):

Criticized loans


$    340,943

$       362,295

$       248,264

$       148,580

$       120,801

Classified loans


114,884

132,650

108,594

98,127

95,162

Total criticized and classified loans


$    455,827

$       494,945

$       356,858

$       246,707

$       215,963

Loans past due 30-89 days / total portfolio loans (3)


0.19


%

0.29

%

0.16

%

0.28

%

0.32

%

Loans past due 90 days or more / total portfolio loans


0.12

0.08

0.09

0.33

0.14

Non-performing loans / total portfolio loans


0.36

0.38

0.38

0.37

0.38

Non-performing assets/total portfolio loans, other

real estate and repossessed assets


0.36

0.38

0.38

0.38

0.39

Non-performing assets / total assets


0.23

0.25

0.26

0.25

0.26

Criticized and classified loans / total portfolio loans


4.26

4.59

3.25

2.23

2.09



Allowance for credit losses

Allowance for credit losses – loans


$    160,040

$       185,827

$       185,109

$       168,475

$       114,272

Allowance for credit losses – loan commitments


6,731

9,514

10,829

10,685

5,572

Provision for credit losses


(27,958)

(209)

16,288

61,841

29,821

Net loan and deposit account overdraft charge-offs and recoveries


648

524

(133)

1,942

4,716

Annualized net loan charge-offs and recoveries /average loans


0.02


%

0.02

%

(0.00)

%

0.07

%

0.18

%

Allowance for credit losses – loans / total portfolio loans


1.50


%

1.72

%

1.68

%

1.52

%

1.10

%

Allowance for credit losses – loans / total portfolio loans excluding PPP loans


1.62


%

1.85

%

1.83

%

1.65

%

1.10

%

Allowance for credit losses – loans / non-performing loans


4.20


x

4.55

x

4.47

x

4.15

x

2.87

x

Allowance for credit losses – loans / non-performing loans and

loans past due 


2.24


x

2.29

x

2.68

x

1.56

x

1.32

x



Quarter Ended



Mar. 31,


Dec. 31,


Sept. 30,


June 30,


Mar. 31,



2021


2020


2020


2020


2020



Capital ratios

Tier I leverage capital


10.74


%

10.51

%

10.18

%

9.09

%

9.64

%

Tier I risk-based capital


14.95

14.72

14.29

12.59

12.51

Total risk-based capital


17.58

17.58

17.18

15.33

14.83

Common equity tier 1 capital ratio (CET 1)


13.65

13.40

12.99

12.59

12.51

Average shareholders’ equity to average assets


16.65

16.59

15.92

15.57

16.43

Tangible equity to tangible assets (4)


10.30

10.52

10.27

9.09

9.65

Tangible common equity to tangible assets (4)


9.39

9.58

9.33

9.09

9.65


(1) Excludes non-performing loans.


(2) Criticized and classified commercial loans may include loans that are also reported as non-performing or past due.


(3) Total portfolio loans includes $823.8 million of PPP loans as of March 31, 2021.


(4) See non-GAAP financial measures for additional information relating to the calculation of this ratio.

 


WESBANCO, INC.


NON-GAAP FINANCIAL MEASURES


Page 11

The following non-GAAP financial measures used by WesBanco provide information useful to investors in understanding WesBanco’s operating performance and trends, and facilitate comparisons with the performance of WesBanco’s peers. The following tables summarize the non-GAAP financial measures derived from amounts reported in WesBanco’s financial statements.



Three Months Ended



Mar. 31,



Dec. 31,



Sept. 30,



June 30,



Mar. 31,


(unaudited, dollars in thousands, except shares and per share amounts)



2021



2020



2020



2020



2020


Return on average assets, excluding after-tax restructuring and merger-related expenses:

Net income available to common shareholders


$             70,584

$             50,210

$           41,305

$             4,488

$           23,396

Plus: after-tax restructuring and merger-related expenses  (1)


672

383

2,850

370

4,080

Net income available to common shareholders excluding after-tax restructuring and merger-related expenses


71,256

50,593

44,155

4,858

27,476

Average total assets


$     16,636,258

$      16,546,761

$    16,719,717

$    16,715,211

$    15,784,939

Return on average assets, excluding after-tax restructuring and merger-related expenses (annualized)  (2)


1.74%

1.22%

1.05%

0.12%

0.70%


Return on average equity, excluding after-tax restructuring and merger-related expenses:

Net income available to common shareholders


$             70,584

$             50,210

$           41,305

$             4,488

$           23,396

Plus: after-tax restructuring and merger-related expenses  (1)


672

383

2,850

370

4,080

Net income available to common shareholders excluding after-tax restructuring and merger-related expenses 


71,256

50,593

44,155

4,858

27,476

Average total shareholders’ equity


2,770,416

2,744,936

2,662,513

2,602,938

2,594,069

Return on average equity, excluding after-tax  restructuring and merger-related expenses (annualized)  (2)


10.43%

7.33%

6.60%

0.75%

4.26%


Return on average tangible equity:

Net income available to common shareholders


$             70,584

$             50,210

$           41,305

$             4,488

$           23,396

Plus: amortization of intangibles (1)


2,288

2,628

2,643

2,658

2,665

Net income available to common shareholders before amortization of intangibles 


72,872

52,838

43,948

7,146

26,061

Average total shareholders’ equity


2,770,416

2,744,936

2,662,513

2,602,938

2,594,069

Less: average goodwill and other intangibles, net of def. tax liability


(1,148,171)

(1,150,184)

(1,150,549)

(1,152,856)

(1,112,327)

Average tangible equity


$       1,622,245

$        1,594,752

$      1,511,964

$      1,450,082

$      1,481,742

Return on average tangible equity (annualized)  (2)


18.22%

13.18%

11.56%

1.98%

7.07%

Average tangible common equity


$       1,477,736

$        1,450,243

$      1,431,657

$      1,450,082

$      1,481,742

Return on average tangible common equity (annualized)  (2)


20.00%

14.49%

12.21%

1.98%

7.07%


Return on average tangible equity, excluding after-tax restructuring and merger-related expenses:

Net income available to common shareholders


$             70,584

$             50,210

$           41,305

$             4,488

$           23,396

Plus: after-tax restructuring and merger-related expenses  (1)


672

383

2,850

370

4,080

Plus: amortization of intangibles  (1)


2,288

2,628

2,643

2,658

2,665

Net income available to common shareholders before amortization of intangibles 

     and excluding after-tax restructuring and merger-related expenses


73,544

53,221

46,798

7,516

30,141

Average total shareholders’ equity


2,770,416

2,744,936

2,662,513

2,602,938

2,594,069

Less: average goodwill and other intangibles, net of def. tax liability


(1,148,171)

(1,150,184)

(1,150,549)

(1,152,856)

(1,112,327)

Average tangible equity


$       1,622,245

$        1,594,752

$      1,511,964

$      1,450,082

$      1,481,742

Return on average tangible equity, excluding after-tax  restructuring and merger-related expenses (annualized)  (2)


18.39%

13.28%

12.31%

2.08%

8.18%

Average tangible common equity


$       1,477,736

$        1,450,243

$      1,431,657

$      1,450,082

$      1,481,742

Return on average tangible common equity, excluding after-tax restructuring and merger-related expenses (annualized)  (2)


20.18%

14.60%

13.00%

2.08%

8.18%


Efficiency ratio:

Non-interest expense


$             86,327

$             88,069

$           89,943

$           85,502

$           91,333

Less: restructuring and merger-related expense


(851)

(484)

(3,608)

(468)

(5,164)

Non-interest expense excluding restructuring and merger-related expense


85,476

87,585

86,335

85,034

86,169

Net interest income on a fully taxable equivalent basis


117,517

120,790

121,705

120,156

121,346

Non-interest income


33,208

32,705

34,612

32,860

28,009

Net interest income on a fully taxable equivalent basis plus non-interest income


$          150,725

$           153,495

$         156,317

$         153,016

$         149,355

Efficiency ratio


56.71%

57.06%

55.23%

55.57%

57.69%


Net income available to common shareholders, excluding after-tax restructuring and merger-related expenses:

Net income available to common shareholders


$             70,584

$             50,210

$           41,305

$             4,488

$           23,396

Add: After-tax restructuring and merger-related expenses (1)


672

383

2,850

370

4,080

Net income available to common shareholders, excluding after-tax restructuring and merger-related expenses


$             71,256

$             50,593

$           44,155

$             4,858

$           27,476


Net income per common share – diluted, excluding after-tax restructuring and merger-related expenses:

Net income per common share – diluted


$                 1.05

$                 0.75

$               0.61

$               0.07

$               0.35

Add: After-tax restructuring and merger-related expenses per common share – diluted (1)


0.01

0.01

0.05

(0.00)

0.06

Net income per common share – diluted, excluding after-tax restructuring and merger-related expenses


$                 1.06

$                 0.76

$               0.66

$               0.07

$               0.41



Period End



Mar. 31,



Dec. 31, 



Sept. 30,



June 30,



Mar. 31,



2021



2020



2020



2020



2020


Tangible book value per share:

Total shareholders’ equity


$       2,785,522

$        2,756,737

$      2,732,966

$      2,569,521

$      2,586,060

Less:  goodwill and other intangible assets, net of def. tax liability


(1,146,874)

(1,149,161)

(1,150,939)

(1,151,523)

(1,154,033)

Less: preferred shareholder’s equity


(144,484)

(144,484)

(144,529)





Tangible common equity


1,494,164

1,463,092

1,437,498

1,417,998

1,432,027

Common shares outstanding


67,282,134

67,254,706

67,216,012

67,211,192

67,058,155

Tangible book value per share


$               22.21

$               21.75

$             21.39

$             21.10

$             21.36


Tangible common equity to tangible assets:

Total shareholders’ equity


$       2,785,522

$        2,756,737

$      2,732,966

$      2,569,521

$      2,586,060

Less:  goodwill and other intangible assets, net of def. tax liability


(1,146,874)

(1,149,161)

(1,150,939)

(1,151,523)

(1,154,033)

Tangible equity


1,638,648

1,607,576

1,582,027

1,417,998

1,432,027

Less: preferred shareholder’s equity


(144,484)

(144,484)

(144,529)





Tangible common equity


1,494,164

1,463,092

1,437,498

1,417,998

1,432,027

Total assets


17,057,788

16,425,610

16,552,140

16,755,395

15,995,572

Less:  goodwill and other intangible assets, net of def. tax liability


(1,146,874)

(1,149,161)

(1,150,939)

(1,151,523)

(1,154,033)

Tangible assets


$     15,910,914

$      15,276,449

$    15,401,201

$    15,603,872

$    14,841,539

Tangible equity to tangible assets


10.30%

10.52%

10.27%

9.09%

9.65%

Tangible common equity to tangible assets


9.39%

9.58%

9.33%

9.09%

9.65%


(1) Tax effected at 21% for all periods presented.


(2) The ratios are annualized by utilizing actual numbers of days in the quarter versus the year.

 


WESBANCO, INC.




ADDITIONAL
NON-GAAP FINANCIAL MEASURES


Page 12

The following non-GAAP financial measures used by WesBanco provide information useful to investors in understanding WesBanco’s operating performance and trends, and
facilitate comparisons with the performance of WesBanco’s peers. The following tables summarize the non-GAAP financial measures derived from amounts reported in
WesBanco’s financial statements.



Three Months Ended



Mar. 31,



Dec. 31,



Sept. 30,



June 30,



Mar. 31,


(unaudited, dollars in thousands, except shares and per share amounts)



2021



2020



2020



2020



2020


Pre-tax, pre-provision income:

Income before provision for income taxes


$         91,317

$        64,557

$        48,974

$          4,530

$          27,017

Add: provision for credit losses


(27,958)

(209)

16,288

61,841

29,821

Pre-tax, pre-provision income


$         63,359

$        64,348

$        65,262

$        66,371

$          56,838


Pre-tax, pre-provision income, excluding restructuring and merger-related expenses:

Income before provision for income taxes


$         91,317

$        64,557

$        48,974

$          4,530

$          27,017

Add: provision for credit losses


(27,958)

(209)

16,288

61,841

29,821

Add: restructuring and merger-related expenses


851

484

3,608

468

5,164

Pre-tax, pre-provision income, excluding restructuring and merger-related expenses


$         64,210

$        64,832

$        68,870

$        66,839

$          62,002


Return on average assets, excluding certain items (1):

Income before provision for income taxes


$         91,317

$        64,557

$        48,974

$          4,530

$          27,017

Add: provision for credit losses


(27,958)

(209)

16,288

61,841

29,821

Add: restructuring and merger-related expenses


851

484

3,608

468

5,164

Pre-tax, pre-provision income, excluding restructuring and merger-related expenses


64,210

64,832

68,870

66,839

62,002

Average total assets


$ 16,636,258

$ 16,546,761

$ 16,719,717

$ 16,715,211

$   15,784,939

Return on average assets, excluding certain items (annualized)  (1) (2)


1.57%

1.56%

1.64%

1.61%

1.58%


Return on average equity, excluding certain items (1):

Income before provision for income taxes


$         91,317

$        64,557

$        48,974

$          4,530

$          27,017

Add: provision for credit losses


(27,958)

(209)

16,288

61,841

29,821

Add: restructuring and merger-related expenses


851

484

3,608

468

5,164

Pre-tax, pre-provision income, excluding restructuring and merger-related expenses


64,210

64,832

68,870

66,839

62,002

Average total shareholders’ equity


2,770,416

2,744,936

2,662,513

2,602,938

2,594,069

Return on average equity, excluding certain items (annualized) (1) (2)


9.40%

9.40%

10.29%

10.33%

9.61%


Return on average tangible equity, excluding certain items (1):

Income before provision for income taxes


$         91,317

$        64,557

$        48,974

$          4,530

$          27,017

Add: provision for credit losses


(27,958)

(209)

16,288

61,841

29,821

Add: amortization of intangibles


2,896

3,327

3,346

3,365

3,374

Add: restructuring and merger-related expenses


851

484

3,608

468

5,164

Income before provision, restructuring and merger-related expenses and amortization of intangibles


67,106

68,159

72,216

70,204

65,376

Average total shareholders’ equity


2,770,416

2,744,936

2,662,513

2,602,938

2,594,069

Less: average goodwill and other intangibles, net of def. tax liability


(1,148,171)

(1,150,184)

(1,150,549)

(1,152,856)

(1,112,327)

Average tangible equity


$   1,622,245

$   1,594,752

$   1,511,964

$   1,450,082

$     1,481,742

Return on average tangible equity, excluding certain items (annualized) (1) (2)


16.78%

17.00%

19.00%

19.47%

17.75%

Average tangible common equity


$   1,477,736

$   1,450,243

$   1,431,657

$   1,450,082

$     1,481,742

Return on average tangible common equity, excluding certain items (annualized) (1) (2)


18.42%

18.70%

20.07%

19.47%

17.75%


(1) Certain items excluded from the calculations consist of credit provisions, tax provisions and restructuring and merger-related expenses.


(2) The ratios are annualized by utilizing actual numbers of days in the quarter versus the year.

 

 

 

 

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/wesbanco-announces-first-quarter-2021-financial-results-301278400.html

SOURCE WesBanco, Inc.

Rollins, Inc. Announces Regular Quarterly Cash Dividend

PR Newswire

ATLANTA, April 27, 2021 /PRNewswire/ — Rollins, Inc. (NYSE: ROL), a premier global consumer and commercial services company announced that the Board of Directors declared a regular quarterly cash dividend on its common stock of $0.08 per share payable June 10, 2021 to stockholders of record at the close of business on May 10, 2021.

Rollins, Inc. is a premier global consumer and commercial services company.  Through its family of leading brands, Orkin, HomeTeam Pest Defense, Clark Pest Control, Orkin Canada, Western Pest Services, Northwest Exterminating, McCall Service, Inc., Critter Control, The Industrial Fumigant Company, Trutech, Orkin Australia, Waltham Services, OPC Services, PermaTreat, Rollins UK, Aardwolf Pestkare, Crane Pest Control and MissQuito, the Company provides essential pest control services and protection against termite damage, rodents and insects to more than two million customers in North America, South America, Europe, Asia, Africa, and Australia from more than 700 locations. You can learn more about Rollins and its subsidiaries by visiting our web sites at www.orkin.com, www.pestdefense.com, www.clarkpest.com, www.orkincanada.ca, www.westernpest.com, www.callnorthwest.com, www.mccallservice.com,  www.crittercontrol.com, www.indfumco.com, www.trutechinc.com, www.orkinau.com, www.walthamservices.com, www.opcpest.com, www.permatreat.com, www.safeguardpestcontrol.co.uk, www.aardwolfpestkare.com,  www.cranepestcontrol.com, www.missquito.com and www.rollins.com. You can also find this and other news releases at www.rollins.com by accessing the news releases button.

ROL-Div

For Further Information Contact
Eddie Northen (404) 888-2242

Cision View original content:http://www.prnewswire.com/news-releases/rollins-inc-announces-regular-quarterly-cash-dividend-301278406.html

SOURCE Rollins, Inc.

FMC Corporation Declares Quarterly Dividend

PR Newswire

PHILADELPHIA, April 27, 2021 /PRNewswire/ — 

FMC Corporation (NYSE: FMC) announced today that its board of directors declared a regular quarterly dividend of 48 cents per share, payable on July 15, 2021, to shareholders of record as of the close of business on June 30, 2021.  

About FMC

FMC Corporation, an agricultural sciences company, provides innovative solutions to growers around the world with a robust product portfolio fueled by a market-driven discovery and development pipeline in crop protection, plant health, and professional pest and turf management. This powerful combination of advanced technologies includes leading insect control products based on Rynaxypyr® and Cyazypyr® active ingredients; Authority®, Boral®, Centium®, Command® and Gamit® branded herbicides; Talstar® and Hero® branded insecticides; and flutriafol-based fungicides. The FMC portfolio also includes biologicals such as Quartzo® and Presence® bionematicides. FMC Corporation employs approximately 6,400 employees around the globe. To learn more, please visit www.fmc.com.

FMC, the FMC logo, Rynaxypyr, Cyazypyr, Authority, Boral, Centium, Command, Gamit, Talstar, Hero, Quartzo and Presence are trademarks of FMC Corporation or an affiliate. Always read and follow all label directions, restrictions and precautions for use. Products listed here may not be registered for sale or use in all states, countries or jurisdictions. Hero® insecticide is a restricted use pesticide in the United States.

The Company’s investor relations website, located at https://investors.fmc.com, should be considered as a recognized channel of distribution, and the Company may periodically post important information to the website for investors, including information that the Company may wish to disclose publicly for purposes of complying with the federal securities laws.  After April 27, 2021, this type of information will no longer be regularly provided by press release but will continue to be posted on the investor relations website.

Statement under the Safe Harbor Provisions of the Private Securities Litigation Reform Act of 1995:  This release contains forward-looking statements, which are based on management’s current views and assumptions regarding future events, future business conditions and the outlook for the company based on currently available information. These statements involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any results, levels of activity, performance or achievements expressed or implied by any forward-looking statement. These factors include, among other things, the risk factors and other cautionary statements included within FMC’s 2020 Form 10-K filed with the SEC as well as other SEC filings and public communications. FMC cautions readers not to place undue reliance on any such forward-looking statements, which speak only as of the date made. Forward-looking statements are qualified in their entirety by the above cautionary statement. FMC undertakes no obligation, and specifically disclaims any duty, to update or revise any forward-looking statements to reflect events or circumstances arising after the date on which they were made, except as otherwise required by law.

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/fmc-corporation-declares-quarterly-dividend-301278252.html

SOURCE FMC Corporation

Nikola Corporation Announces Date for First Quarter 2021 Results and Webcast

PR Newswire

PHOENIX, April 27, 2021 /PRNewswire/ — Nikola Corporation (NASDAQ: NKLA), a global leader in zero-emissions transportation and infrastructure solutions, today announced it will report its first quarter ended March 31, 2021 financial results after market close on Friday, May 7, 2021. On that day, Nikola’s management will hold a conference call and webcast at 4:30 p.m. ET (1:30 p.m. PT) to review and discuss the company’s business and outlook.

What: Date of Nikola Q1 2021 Financial Results and Q&A Webcast
When: Friday, May 7, 2021
Time: 4:30 p.m. ET (1:30 p.m. PT)
Webcast: https://nikolamotor.com/investors/news?active=events (live and replay)
An archived webcast of the conference call will be accessible from the Investor Relations section of the company’s website https://nikolamotor.com/investors/news?active=events.

ABOUT NIKOLA CORPORATION:
Nikola Corporation is globally transforming the transportation industry. As a designer and manufacturer of zero-emission battery-electric and hydrogen-electric vehicles, electric vehicle drivetrains, vehicle components, energy storage systems, and hydrogen station infrastructure, Nikola is driven to revolutionize the economic and environmental impact of commerce as we know it today. Founded in 2015, Nikola Corporation is headquartered in Phoenix, Arizona. For more information, visit www.nikolamotor.com or Twitter @nikolamotor.

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/nikola-corporation-announces-date-for-first-quarter-2021-results-and-webcast-301278352.html

SOURCE Nikola Corporation

Yum China Reports First Quarter 2021 Results

Total Revenues grew 46%. System Sales grew 34% and Same-Store Sales were up 10% in constant currency

Opened 315 new stores and reported $342 million Operating Profit

PR Newswire

SHANGHAI, April 27, 2021 /PRNewswire/ — Yum China Holdings, Inc. (the “Company” or “Yum China“) (NYSE: YUMC and HKEX: 9987) today reported unaudited results for the first quarter ended March 31, 2021.

Impact of COVID-19 Outbreak and Mitigation Efforts 

Yum China reported substantial year-over-year growth in the first quarter, as the Company began to lap prior year periods that were impacted by COVID-19. System sales growth was mainly attributable to same-store sales growth, new unit contribution and substantially fewer temporary store closures. Operating Profit growth was further driven by lower commodity prices and productivity gains.

First quarter sales were impacted by regional resurgences of COVID-19 before the Chinese New Year and tightened public health measures across China. The tightened measures and associated consumer caution resulted in smaller gatherings and a noticeably reduced volume of travel. Our transportation and tourist locations, representing high single digits of our store mix, were significantly affected by the decline in travel. According to government statistics, the number of travelers was down approximately 40% versus 2020, and down approximately 70% versus 2019, when compared to the corresponding 40-day Chinese New Year holiday periods. These impacts were more pronounced for KFC, which accounts for most of our stores in these locations.

The pandemic has also introduced volatility and uncertainty to our operations. The Company acted and reacted nimbly to changing conditions. By planning for a wide range of possible situations, our team worked tirelessly to meet shifting demand across city tiers, trade zones and sales channels. Leveraging our digital capabilities, direct connection with consumers and in-house supply chain, we were able to deftly adjust offers and promotions to changing market conditions. We deployed resources flexibly to help ensure the best possible levels of restaurant staffing and delivery riders, as demand patterns shifted.

Looking ahead, the Company expects a full recovery of same-store sales to pre-COVID-19 levels to take time, and the unevenness of recovery to linger for several reasons. Public health measures and social distancing behaviors persist as occasional outbreaks, such as those in the first quarter and more recent outbreaks in Yunnan province, remind people of the lingering risks. Dine-in traffic, as well as sales at our transportation locations, remains well below 2019 levels. Accordingly, the Company will continue to focus on driving the sales recovery while ensuring the safety of our employees and customers.

First
Quarter Highlights

  • Total
    revenues increased 46% year over year to $2.56 billion from $1.75 billion (a 36% increase excluding foreign currency translation (“F/X”)).
  • Total system sales increased 34% year over year, with increases of 24% at KFC and 57% at Pizza Hut, excluding F/X.
  • Same-store sales increased 10% year over year, with increases of 5% at KFC and 38% at Pizza Hut, excluding F/X.
  • Opened 315 new stores during the quarter; total store count reached 10,725 as of March 31, 2021.
  • Restaurant margin was 18.7%, compared with 10.7% in the prior year period.
  • Operating
    Profit increased 250% year over year to $342 million from $97 million (a 227% increase excluding F/X).
  • Adjusted Operating Profit increased 249% year over year to $345 million from $98 million (a 227% increase excluding F/X).
  • Effective tax rate was 29.6%.
  • Net
    Income increased 272% to $230 million from $62 million in the prior year period, primarily due to the increase in Operating Profit.
  • Adjusted Net Income increased 271% to $233 million from $63 million in the prior year period (a 249% increase excluding the mark-to-market losses of $16 million and $8 million in the first quarter of 2021 and 2020, respectively, from our equity investments; a 225% increase if further excluding F/X).
  • Dilute
    d EPS increased 231% to $0.53 from $0.16 in the prior year period.
  • Adjusted Diluted EPS increased 238% to $0.54 from $0.16 in the prior year period (a 217% increase excluding the mark-to-market losses from our equity investments in the first quarter of 2021 and 2020; a 194% increase if further excluding F/X).
  • Results include the consolidation of Huang Ji Huang since April 2020, and Suzhou KFC since August 2020.

Key Financial Results


First Quarter 2021


% Change


System Sales


Same-Store Sales


Net New Units


Operating Profit

Yum China

+34

+10

+15

+250

        KFC

+24

+5

+11

+113

        Pizza Hut

+57

+38

+5

NM

 


First Quarter

(in US$ million, except


% Change

per share data and percentages)


2021


2020


Reported


Ex F/X

Operating Profit

$

342

$

97

+250

+227

Adjusted Operating Profit(1)

$

345

$

98

+249

+227

Net Income

$

230

$

62

+272

+244

Adjusted Net Income(1)

$

233

$

63

+271

+244

Basic Earnings Per Common Share

$

0.55

$

0.16

+244

+219

Adjusted Basic Earnings Per

  Common Share(1)

$

0.55

$

0.17

+224

+200

Diluted Earnings Per Common Share

$

0.53

$

0.16

+231

+206

Adjusted Diluted Earnings Per

  Common Share(1)

$

0.54

$

0.16

+238

+213

 


(1) See “Reconciliation of Reported GAAP Results to non-GAAP Adjusted Measures” included in the accompanying tables of this release for further details.


Note:  All comparisons are versus the same period a year ago.

NM refers to not meaningful.

Percentages may not recompute due to rounding.

System sales and same-store sales percentages exclude the impact of F/X. Effective January 1, 2018, temporary store closures are normalized in the same-store sales calculation by
excluding the period during which stores are temporarily closed.

CEO
and CFO Comments

Joey Wat, CEO of Yum China, commented, “Our first quarter results once again demonstrated the resilience of Yum China and were accomplished by our dedicated and tireless team of over 400,000 people. We delivered solid sales growth and operating profit amid challenging market conditions. Our operations and supply chain teams overcame a wide array of challenges and uncertainties, managed potential disruptions and delivered robust operations for our stores. Our brands adapted quickly to an unusual Chinese New Year, driving on- and off-premise dining demand with compelling offers and flexible resource planning. KFC continued its journey of accelerated growth, while Pizza Hut made significant strides in making its business more resilient.”

Wat continued, “We remain optimistic about our long-term growth opportunity in China, which is reflected in our vigorous pace of investment. We accelerated store network expansion, opening 315 new stores during the quarter. As part of our end-to-end digitization initiatives, we are digitizing and automating our restaurants to improve operational efficiency. Leveraging emerging technologies, we have been enhancing our ability to manage inventory, product quality and kitchen processes. Furthermore, we continue to fortify our supply chain to give us more operational flexibility, allow us to be more responsive and to grow even faster. During the quarter, we took a 5% equity interest in our largest poultry supplier Sunner to deepen collaboration, and broke ground to build an intelligent supply chain support center in Chengdu. All these initiatives are essential to help accelerate our growth in the years ahead.”  

Andy Yeung, CFO of Yum China, added, “While we are pleased with the first quarter performance, sales were impacted by regional outbreaks and significantly reduced travel volumes. The impacts of COVID-19 are subsiding, but we continue to expect the recovery of same-store sales to 2019 levels to take time and the recovery path to remain uneven and non-linear. In the short term, the top priority of our business is to drive consumer traffic back to our stores. We plan to invest more in our marketing, value proposition, digital engagement and customer service. On the other hand, we are also seeing early signs of inflationary pressure in commodity prices and wages as the economy continues to recover. Despite the lingering effects of COVID-19, we will continue to invest to drive sustainable long-term growth.”

Dividends

  • The Board of Directors declared a cash dividend of $0.12 per share on Yum China’s common stock, payable as of the close of business on June 18, 2021 to shareholders of record as of the close of business on May 25, 2021.

Digital and Delivery 

  • The KFC and Pizza Hut loyalty programs exceeded 315 million members combined as of quarter-end. Member sales increased to approximately 61% of system sales in the first quarter of 2021.
  • Delivery contributed approximately 29% of KFC and Pizza Hut’s Company sales in the first quarter of 2021, a decrease of approximately six percentage points from the prior year period due to recovery of dine-in volumes.
  • Digital orders, including delivery, mobile orders and kiosk orders, accounted for approximately 84% of KFC and Pizza Hut’s Company sales in the first quarter of 2021.

KFC and Pizza Hut Total


First Quarter


2021


2020

        Member count (as of period-end)

315 million+

250 million+

        Member sales as % of system sales

~61%

~59%

        Delivery as % of Company sales

~29%

~35%

        Digital orders as % of Company sales

~84%

~80%

New-Unit Development and Asset Upgrade

  • The Company opened 315 new stores in the first quarter of 2021, mainly driven by development of the KFC brand.
  • The Company remodeled 108 stores in the first quarter of 2021.


New Units


Restaurant Count


First Quarter


As of March 31


2021


2021


2020

Yum China

315

10,725

9,295

   KFC

253

7,373

6,661

   Pizza Hut

44

2,382

2,271

   Others(2)

18

970

363

 


(2) Others include Taco Bell, Little Sheep, Huang Ji Huang, East Dawning, COFFii & JOY and Lavazza.

Restaurant Margin

  • Restaurant margin was 18.7% in the first quarter of 2021, compared with 10.7% in the prior year period, primarily attributable to sales leverage, lower commodity prices and higher productivity, partially offset by increased value promotions, lower temporary relief provided by landlords and government agencies and wage inflation.


First Quarter


2021


2020


ppts change

Yum China

18.7

%

10.7

%

+8.0

   KFC

19.9

%

13.6

%

+6.3

   Pizza Hut

15.3

%

0.3

%

+15.0

2021 Outlook

The Company’s fiscal year 2021 targets remain unchanged:

  • To open approximately 1,000 new stores (gross).
  • To make capital expenditures of approximately $600 million.

Other Updates

  • On March 16, 2021, the Company announced that it acquired a 5% equity interest in Fujian Sunner Development Co., Ltd. (“Sunner”), the Company’s largest poultry supplier, for total cash consideration of approximately $261 million. This strategic investment is intended to enhance the Company’s supply chain security and deepen its collaboration with Sunner, especially in product development and menu innovation.
  • On March 26, 2021, Yum China announced the beginning of construction of its Southwest Supply Chain Support Center in Chengdu with a total investment of approximately $28 million. This center is part of Yum China’s intelligent supply chain initiative that integrates Internet of Things technology, big data platforms and high-quality cold chain logistics facilities to support the Company’s rapid development.

Note on Non-GAAP Adjusted Measures

Reported GAAP results include Special Items, which are excluded from non-GAAP adjusted measures. Special Items are not allocated to any segment and therefore only impact reported GAAP results of Yum China. See “Reconciliation of Reported GAAP Results to Non-GAAP Adjusted Measures” within this release.

Conf
erence Call

Yum China’s management will hold an earnings conference call at 8:00 p.m. U.S. Eastern Time on Tuesday, April 27, 2021 (8:00 a.m.Beijing/Hong Kong Time on Wednesday, April 28, 2021).  

Operator-assisted conference calls are not available at the moment. Please register in advance of the conference through the link provided below. Upon registering, you will be provided with participant dial-in numbers, a passcode and a unique registrant ID.

Pre-registration Link:              http://apac.directeventreg.com/registration/event/2388999
Conference ID:                       2388999

A live webcast of the call may also be accessed at https://edge.media-server.com/mmc/p/6urc2ev7.

A replay of the conference call will be available two hours after the call ends until 10:00 a.m. U.S. Eastern Time on Wednesday, May 5, 2021 (10:00 p.m.Beijing/Hong Kong Time on Wednesday, May 5, 2021) and may be accessed by phone at the following numbers:

U.S.:                                       1 855 452 5696
Mainland China:                     400 602 2065 or 800 870 0206
Hong Kong:                            +852 3051 2780
U.K.:                                        0808 234 0072
International:                           +61 2 8199 0299

Replay access code:               2388999

Additionally, this earnings release, the accompanying slides, a live webcast and an archived webcast of this conference call will be available at Yum China’s Investor Relations website at http://ir.yumchina.com.  

For important news and information regarding Yum China, including our filings with the U.S. Securities and Exchange Commission and the Hong Kong Stock Exchange, visit Yum China’s Investor Relations website at http://ir.yumchina.com. Yum China uses this website as a primary channel for disclosing key information to its investors, some of which may contain material and previously non-public information.

Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, including under “2021 Outlook.” We intend all forward-looking statements to be covered by the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements generally can be identified by the fact that they do not relate strictly to historical or current facts and by the use of forward-looking words such as “expect,” “expectation,” “believe,” “anticipate,” “may,” “could,” “intend,” “belief,” “plan,” “estimate,” “target,” “predict,” “project,” “likely,” “will,” “continue,” “should,” “forecast,” “outlook” or similar terminology. These statements are based on current estimates and assumptions made by us in light of our experience and perception of historical trends, current conditions and expected future developments, as well as other factors that we believe are appropriate and reasonable under the circumstances, but there can be no assurance that such estimates and assumptions will prove to be correct. Forward-looking statements include, without limitation, statements regarding the future strategies, business plans, investment, dividend and share repurchase plans, earnings, performance and returns of Yum China, anticipated effects of population and macroeconomic trends, the expected impact of the COVID-19 outbreak, the anticipated effects of our innovation, digital and delivery capabilities and investments on growth and beliefs regarding the long-term drivers of Yum China’s business. Forward-looking statements are not guarantees of performance and are inherently subject to known and unknown risks and uncertainties that are difficult to predict and could cause our actual results or events to differ materially from those indicated by those statements. We cannot assure you that any of our expectations, estimates or assumptions will be achieved. The forward-looking statements included in this press release are only made as of the date of this press release, and we disclaim any obligation to publicly update any forward-looking statement to reflect subsequent events or circumstances, except as required by law. Numerous factors could cause our actual results or events to differ materially from those expressed or implied by forward-looking statements, including, without limitation: whether we are able to achieve development goals at the times and in the amounts currently anticipated, if at all, the success of our marketing campaigns and product innovation, our ability to maintain food safety and quality control systems, changes in public health conditions, including the COVID-19 outbreak, our ability to control costs and expenses, including tax costs, as well as changes in political, economic and regulatory conditions in China. In addition, other risks and uncertainties not presently known to us or that we currently believe to be immaterial could affect the accuracy of any such forward-looking statements. All forward-looking statements should be evaluated with the understanding of their inherent uncertainty. You should consult our filings with the Securities and Exchange Commission (including the information set forth under the captions “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in our Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q) for additional detail about factors that could affect our financial and other results.

About Yum China Holdings, Inc.

Yum China Holdings, Inc. is a licensee of Yum! Brands in mainland China. It has exclusive rights in mainland China to KFC, China’s leading quick-service restaurant brand, Pizza Hut, the leading casual dining restaurant brand in China, and Taco Bell, a California-based restaurant chain serving innovative Mexican-inspired food. Yum China also owns the Little Sheep, Huang Ji Huang, East Dawning and COFFii & JOY concepts outright. In addition, Yum China has partnered with Lavazza to explore and develop the Lavazza coffee shop concept in China. The Company had 10,725 restaurants in over 1,500 cities at the end of March 2021. Yum China ranked # 361 on the Fortune 500 list for 2020. Yum China has been named the Industry Leader for the Restaurant & Leisure Facilities Industry in the 2020 Dow Jones Sustainability Indices. In 2021, Yum China was named to the Bloomberg Gender-Equality Index and was certified as a Top Employer 2021 in China by the Top Employers Institute, both for the third consecutive year. For more information, please visit http://ir.yumchina.com.


Investor Relations Contact:

Tel: +86 21 2407 7556 / +852 2267 5801




[email protected]


  

 


mailto:
 


Media Contact
:

Tel: +86 21 2407 7510




[email protected]


 

 


Yum China Holdings, Inc.


Condensed Consolidated Statements of Income


(in US$ million, except per share data)


(unaudited)


Quarter Ended


% Change


3/31/2021


3/31/2020


B/(W)


Revenues

Company sales

$    2,331

$    1,548

51

Franchise fees and income

42

35

17

Revenues from transactions with
   franchisees and unconsolidated affiliates

171

161

6

Other revenues

13

10

29

Total revenues

2,557

1,754

46


Costs and Expenses, Net

Company restaurants

Food and paper

704

495

(42)

Payroll and employee benefits

544

394

(38)

Occupancy and other operating expenses

648

494

(31)

Company restaurant expenses

1,896

1,383

(37)

General and administrative expenses

130

99

(32)

Franchise expenses

17

17

3

Expenses for transactions with
   franchisees and unconsolidated affiliates

169

156

(8)

Other operating costs and expenses

11

10

(5)

Closures and impairment (income) expenses, net

(2)

8

 NM 

Other income, net

(6)

(16)

(63)

Total costs and expenses, net

2,215

1,657

(34)


Operating Profit

342

97

250

Interest income, net

15

9

68

Investment loss

(12)

(8)

(42)


Income Before Income Taxes

345

98

251

Income tax provision

(102)

(32)

(218)

Net income – including noncontrolling interests

243

66

268

Net income – noncontrolling interests

13

4

(206)


Net Income – Yum China Holdings, Inc.

$       230

$         62

272

Effective tax rate

29.6%

32.7%

3.1

 ppts. 


Basic Earnings Per Common Share

$      0.55

$      0.16

Weighted-average shares outstanding
    (in millions)

420

376


Diluted Earnings Per Common Share

$       0.53

$       0.16

Weighted-average shares outstanding
    (in millions)

434

386


Cash Dividends Declared Per Common Share

$      0.12

$      0.12

Company sales

100.0%

100.0%

Food and paper

30.2

32.0

1.8

ppts.

Payroll and employee benefits

23.3

25.5

2.2

ppts.

Occupancy and other operating expenses

27.8

31.8

4.0

ppts.

Restaurant margin

18.7%

10.7%

8.0

ppts.

Operating margin

14.7%

6.3%

8.4

ppts.

Percentages may not recompute due to rounding.

 

 


Yum China Holdings, Inc.


KFC Operating Results


(in US$ million)


(unaudited)


Quarter Ended


% Change


3/31/2021


3/31/2020


B/(W)


Revenues

Company sales

$      1,783

$      1,220

46

Franchise fees and income

33

33

(2)

Revenues from transactions with
   franchisees and unconsolidated affiliates

15

16

(6)

Other revenues

1

 NM 

Total revenues

1,832

1,269

44


Costs and Expenses, Net

Company restaurants

Food and paper

540

392

(38)

Payroll and employee benefits

398

287

(39)

Occupancy and other operating expenses

 

490

375

(30)

Company restaurant expenses

1,428

1,054

(36)

General and administrative expenses

55

46

(19)

Franchise expenses

16

16

3

Expenses for transactions with
   franchisees and unconsolidated affiliates

15

16

7

Closures and impairment expenses, net

1

 NM 

Other income, net

(9)

(17)

(45)

Total costs and expenses, net

1,505

1,116

(35)


Operating Profit

$         327

$         153

113

Company sales

100.0%

100.0%

Food and paper

30.3

32.1

1.8

ppts.

Payroll and employee benefits

22.3

23.5

1.2

ppts.

Occupancy and other operating expenses

27.5

30.8

3.3

ppts.

Restaurant margin

19.9%

13.6%

6.3

ppts.

Operating margin

18.3%

12.6%

5.7

ppts.

Percentages may not recompute due to rounding.

 

 


Yum China Holdings, Inc.


Pizza Hut Operating Results


(in US$ million)


(unaudited)


Quarter Ended


% Change


3/31/2021


3/31/2020


B/(W)


Revenues

Company sales

$         538

$         322

67

Franchise fees and income

2

1

90

Revenues from transactions with
   franchisees and unconsolidated affiliates

1

1

91

Total revenues

541

324

67


Costs and Expenses, Net

Company restaurants

Food and paper

160

102

(58)

Payroll and employee benefits

143

104

(36)

Occupancy and other operating expenses

153

115

(34)

Company restaurant expenses

456

321

(42)

General and administrative expenses

25

24

(6)

Franchise expenses

1

1

(38)

Expenses for transactions with
   franchisees and unconsolidated affiliates

1

1

(75)

Closures and impairment (income) expenses, net

 

(2)

5

 NM 

Total costs and expenses, net

481

352

(37)


Operating Profit (Loss)

$           60

$          (28)

 NM 

Company sales

100.0%

100.0%

Food and paper

29.8

31.6

1.8

ppts.

Payroll and employee benefits

26.4

32.4

6.0

ppts.

Occupancy and other operating expenses

28.5

35.7

7.2

ppts.

Restaurant margin

15.3%

0.3%

15.0

ppts.

Operating margin

11.1%

(8.7)%

19.8

ppts.

Percentages may not recompute due to rounding.

 

 


Yum China Holdings, Inc.


Condensed Consolidated Balance Sheets


(in US$ million)


3/31/2021


12/31/2020


(Unaudited)


ASSETS


Current Assets

Cash and cash equivalents

$        1,084

$         1,158

Short-term investments

3,026

3,105

Accounts receivable, net

102

99

Inventories, net

345

398

Prepaid expenses and other current assets

199

176


Total Current Assets

4,756

4,936

Property, plant and equipment, net

1,749

1,765

Operating lease right-of-use assets

2,140

2,164

Goodwill

829

832

Intangible assets, net

234

246

Deferred income tax assets

83

98

Investments in unconsolidated affiliates

48

85

Other assets

998

749


Total Assets

10,837

10,875


LIABILITIES, REDEEMABLE NONCONTROLLING INTEREST
   AND EQUITY

 


Current Liabilities

Accounts payable and other current liabilities

1,800

1,995

Income taxes payable

122

72


Total Current Liabilities

1,922

2,067

Non-current operating lease liabilities

1,882

1,915

Non-current finance lease obligations

28

28

Deferred income tax liabilities

227

227

Other liabilities

165

167


Total Liabilities

4,224

4,404


Redeemable Noncontrolling Interest

12

12


Equity

Common stock,  $0.01 par value; 1,000 million shares authorized; 440 million shares and
    440 million shares issued at March 31, 2021 and December 31, 2020, respectively; 420
    million shares and 420 million shares outstanding at March 31, 2021 and December 31,
    2020, respectively

4

4

Treasury stock

(728)

(728)

Additional paid-in capital

4,664

4,658

Retained earnings

2,285

2,105

Accumulated other comprehensive income

150

167


Total Yum China Holdings, Inc. Stockholders’ Equity

6,375

6,206

Noncontrolling interests

226

253


Total Equity

6,601

6,459


Total Liabilities, Redeemable Noncontrolling Interest and Equity

$      10,837

$       10,875

 

 


Yum China Holdings, Inc.


Condensed Consolidated Statements of Cash Flows


(in US$ million)


(unaudited)



Quarter Ended


3/31/2021


3/31/2020


Cash Flows – Operating Activities

Net income – including noncontrolling interests

$                   243

$                     66

Depreciation and amortization

128

109

Non-cash operating lease cost

101

88

Closures and impairment (income) expenses

(2)

8

Investment loss

12

8

Equity income from investments in unconsolidated affiliates

(17)

(20)

Distributions of income received from unconsolidated affiliates

11

8

Deferred income taxes

15

2

Share-based compensation expense

10

7

Changes in accounts receivable

(3)

9

Changes in inventories

52

57

Changes in prepaid expenses and other current assets

20

10

Changes in accounts payable and other current liabilities

(175)

(192)

Changes in income taxes payable

51

5

Changes in non-current operating lease liabilities

(104)

(102)

Other, net

(11)

(3)


Net Cash Provided by Operating Activities

331

60


Cash Flows – Investing Activities

Capital spending

(165)

(87)

Purchases of short-term investments

(1,180)

(275)

Maturities of short-term investments

1,258

390

Prepayment for investment

(27)

Investment in equity securities

(261)

Other, net

1

1


Net Cash (Used in) Provided by Investing Activities

(347)

2


Cash Flows – Financing Activities

Repurchase of shares of common stock

(8)

Cash dividends paid on common stock

(50)

(45)

Dividends paid to noncontrolling interests

(1)

Other, net

(4)

1


Net Cash Used in Financing Activities

(55)

(52)


Effect of Exchange Rates on Cash, Cash Equivalents and Restricted Cash

(3)

(8)


Net (Decrease) Increase in Cash, Cash Equivalents and Restricted Cash

(74)

2


Cash, Cash Equivalents, and Restricted Cash – Beginning of Period

1,158

1,055


Cash, Cash Equivalents, and Restricted Cash – End of Period

$                1,084

$                1,057

In this press release:

  • The Company provides certain percentage changes excluding the impact of foreign currency translation (“F/X”). These amounts are derived by translating current year results at prior year average exchange rates. We believe the elimination of the F/X impact provides better year-to-year comparability without the distortion of foreign currency fluctuations.
  • System sales growth reflects the results of all restaurants regardless of ownership, including Company-owned, franchise and unconsolidated affiliate restaurants that operate our restaurant concepts, except for non-Company-owned restaurants for which we do not receive a sales-based royalty. Sales of franchise and unconsolidated affiliate restaurants typically generate ongoing franchise fees for the Company at a rate of approximately 6% of system sales. Franchise and unconsolidated affiliate restaurant sales are not included in Company sales in the Condensed Consolidated Statements of Income; however, the franchise fees are included in the Company’s revenues. We believe system sales growth is useful to investors as a significant indicator of the overall strength of our business as it incorporates all of our revenue drivers, Company and franchise same-store sales as well as net unit growth.
  • Effective January 1, 2018, the Company revised its definition of same-store sales growth to represent the estimated percentage change in sales of food of all restaurants in the Company system that have been open prior to the first day of our prior fiscal year, excluding the period during which stores are temporarily closed. We refer to these as our “base” stores. Previously, same-store sales growth represented the estimated percentage change in sales of all restaurants in the Company system that have been open for one year or more, including stores temporarily closed, and the base stores changed on a rolling basis from month to month. This revision was made to align with how management measures performance internally and focuses on trends of a more stable base of stores.
  • Company sales represent revenues from Company-owned restaurants. Company Restaurant profit (“Restaurant profit”) is defined as Company sales less expenses incurred directly by our Company-owned restaurants in generating Company sales. Company restaurant margin percentage is defined as Restaurant profit divided by Company sales.

Reconciliation of Reported GAAP Results to Non-GAAP Adjusted Measures

(in millions, except per share data)

(unaudited)

In addition to the results provided in accordance with U.S. Generally Accepted Accounting Principles (“GAAP”) in this press release, the Company provides non-GAAP measures adjusted for Special Items, which include Adjusted Operating Profit, Adjusted Net Income, Adjusted Earnings Per Common Share (“EPS”), Adjusted Effective Tax Rate and Adjusted EBITDA, which we define as net income including noncontrolling interests adjusted for income tax, interest income, net, investment gain or loss, certain non-cash expenses, consisting of depreciation and amortization as well as store impairment charges, and Special Items.

The following table set forth the reconciliation of the most directly comparable GAAP financial measures to the non-GAAP adjusted financial measures.


Quarter Ended


3/31/2021


3/31/2020


Non-GAAP Reconciliations


Reconciliation of Operating Profit to Adjusted Operating Profit

Operating Profit

$         342

$           97

Special Items, Operating Profit 

(3)

(1)

Adjusted Operating Profit

$         345

$           98


Reconciliation of Net Income to Adjusted Net Income

Net Income – Yum China Holdings, Inc.

$         230

$           62

Special Items, Net Income –Yum China Holdings, Inc.

(3)

(1)

Adjusted Net Income – Yum China Holdings, Inc.

$         233

$           63


Reconciliation of EPS to Adjusted EPS

Basic Earnings Per Common Share

$        0.55

$        0.16

Special Items, Basic Earnings Per Common Share

(0.01)

Adjusted Basic Earnings Per Common Share

$        0.55

$        0.17

Diluted Earnings Per Common Share

$        0.53

$        0.16

Special Items, Diluted Earnings Per Common Share

(0.01)

Adjusted Diluted Earnings Per Common Share

$        0.54

$        0.16


Reconciliation of Effective Tax Rate to Adjusted Effective Tax Rate

Effective tax rate

29.6%

32.7%

Impact on effective tax rate as a result of Special Items

0.3%

0.3%

Adjusted effective tax rate

29.3%

32.4%

Net income, along with the reconciliation to Adjusted EBITDA, is presented below:


Quarter Ended


3/31/2021


3/31/2020


Reconciliation of Net Income to Adjusted EBITDA

Net Income – Yum China Holdings, Inc.

$         230

$           62

Net income – noncontrolling interests

13

4

Income tax provision

102

32

Interest income, net

(15)

(9)

Investment loss

12

8

Operating Profit

342

97

Special Items, Operating Profit

3

1

Adjusted Operating Profit

345

98

Depreciation and amortization

128

109

Store impairment charges

3

12

Adjusted EBITDA

$         476

$         219

 Details of Special Items are presented below:


Quarter Ended


3/31/2021


3/31/2020

Share-based compensation expense for Partner PSU awards(1)

$           (3)

$           (1)

Special Items, Operating Profit

(3)

(1)

Tax effect on Special Items(2)

Special Items, net income – including noncontrolling interests

(3)

(1)

Special Items, net income – noncontrolling interests

Special Items, Net Income –Yum China Holdings, Inc.

$           (3)

$           (1)

Weighted-average Diluted Shares Outstanding (in millions)

434

386

 Special Items, Diluted Earnings Per Common Share 

$      (0.01)

$           —

(1)  In February 2020, the Company granted Partner PSU Awards to select employees who were deemed critical to the Company’s execution of its strategic operating plan. These PSU awards will only vest if threshold performance goals are achieved over a four-year performance period, with the payout ranging from 0% to 200% of the target number of shares subject to the PSU awards. Partner PSU Awards were granted to address increased competition for executive talent, motivate transformational performance and encourage management retention. Given the unique nature of these grants, the Compensation Committee does not intend to grant similar, special grants to the same employees during the performance period. The impact from these special awards is excluded from metrics that management uses to assess the Company’s performance. The Company recognized share-based compensation cost of $3 million and $1 million associated with the Partner PSU Awards for the quarter ended March 31, 2021 and 2020, respectively.

(2)  The tax expense was determined based upon the nature, as well as the jurisdiction, of each Special Item at the applicable tax rate.

The Company excludes impact from Special Items for the purpose of evaluating performance internally. Special Items are not included in any of our segment results. In addition, the Company provides Adjusted EBITDA because we believe that investors and analysts may find it useful in measuring operating performance without regard to items such as income tax, interest income, net, investment gain or loss, depreciation and amortization, store impairment charges, and Special Items. Store impairment charges included as an adjustment item in Adjusted EBITDA primarily resulted from our semi-annual impairment evaluation of long-lived assets of individual restaurants, and additional impairment evaluation whenever events or changes in circumstances indicate that the carrying value of the assets may not be recoverable. If these restaurant-level assets were not impaired, depreciation of the assets would have been recorded and included in EBITDA. Therefore, store impairment charges were a non-cash item similar to depreciation and amortization of our long-lived assets of restaurants. The Company believes that investors and analyst may find it useful in measuring operating performance without regard to such non-cash item.

These adjusted measures are not intended to replace the presentation of our financial results in accordance with GAAP.  Rather, the Company believes that the presentation of these adjusted measures provides additional information to investors to facilitate the comparison of past and present results, excluding those items that the Company does not believe are indicative of our ongoing operations due to their nature. 


Unit Count by Brand


KFC


12/31/2020


New Builds


Closures


Refranchised


3/31/2021

Company-owned

5,872

197

(38)

(1)

6,030

Unconsolidated affiliates

677

31

(4)

704

Franchisees

617

25

(4)

1

639

Total

7,166

253

(46)

7,373


Pizza Hut


12/31/2020


New Builds


Closures


3/31/2021

Company-owned

2,230

42

(17)

2,255

Franchisees

125

2

127

Total

2,355

44

(17)

2,382


Others


12/31/2020


New Builds


Closures


3/31/2021

Company-owned

88

2

(4)

86

Unconsolidated affiliates

4

1

5

Franchisees

893

15

(29)

879

Total

985

18

(33)

970

 

 


Yum China Holdings, Inc.


Segment Results


(in US$ million)


(unaudited)


Quarter Ended 3/31/2021

KFC

Pizza Hut

All Other Segments

Corporate
and
Unallocated(1)

Elimination

Total

Company sales

$      1,783

$         538

$                            10

$                 —

$              —

$      2,331

Franchise fees and income

33

2

7

42

Revenues from transactions with
   franchisees and unconsolidated affiliates(2)

15

1

26

129

171

Other revenues

1

35

2

(25)

13

Total revenues

$      1,832

$         541

$                           78

$               131

$            (25)

$      2,557

Company restaurant expenses

1,428

456

12

1,896

General and administrative expenses

55

25

9

41

130

Franchise expenses

16

1

17

Expenses for transactions with
  franchisees and unconsolidated affiliates(2)

15

1

24

129

169

Other operating costs and expenses

33

3

(25)

11

Closures and impairment income, net

(2)

(2)

Other (income) expenses, net

(9)

3

(6)

Total costs and expenses, net

1,505

481

81

173

(25)

2,215

Operating Profit (Loss)

$         327

$           60

$                           (3)

$                (42)

$              —

$         342


Quarter Ended 3/31/2020

KFC

Pizza Hut

All Other Segments

Corporate
and
Unallocated(1)

Elimination

Total

Company sales

$      1,220

$         322

$                              6

$                 —

$              —

$      1,548

Franchise fees and income

33

1

1

35

Revenues from transactions with
   franchisees and unconsolidated affiliates(2)

16

1

5

139

161

Other revenues

16

1

(7)

10

Total revenues

$      1,269

$         324

$                            28

$               140

$              (7)

$      1,754

Company restaurant expenses

1,054

321

9

(1)

1,383

General and administrative expenses

46

24

8

21

99

Franchise expenses

16

1

17

Expenses for transactions with
  franchisees and unconsolidated affiliates(2)

16

1

4

135

156

Other operating costs and expenses

15

1

(6)

10

Closures and impairment expenses, net

1

5

2

8

Other income, net

(17)

1

(16)

Total costs and expenses, net

1,116

352

38

158

(7)

1,657

Operating Profit (Loss)

$         153

$          (28)

$                         (10)

$                (18)

$              —

$           97

The above tables reconcile segment information, which is based on management responsibility, with our Condensed Consolidated Statements of Income. 

(1)  Amounts have not been allocated to any segment for purpose of making operating decision or assessing financial performance as the transactions are deemed corporate revenues and expenses in nature.

(2)  Primarily includes revenues and associated expenses of transactions with franchisees and unconsolidated affiliates derived from the Company’s central procurement model whereby the Company centrally purchases substantially all food and paper products from suppliers and then sells and delivers to KFC and Pizza Hut restaurants, including franchisees and unconsolidated affiliates.

Cision View original content:http://www.prnewswire.com/news-releases/yum-china-reports-first-quarter-2021-results-301277506.html

SOURCE Yum China Holdings, Inc.

For 12th Year In A Row, J.D. Power Ranks Frost Bank Highest In Texas Retail Banking Customer Satisfaction

PR Newswire

SAN ANTONIO, April 27, 2021 /PRNewswire/ — For the 12th consecutive year, Frost Bank received the highest ranking in customer satisfaction in Texas, as J.D. Power announced its 2021 U.S. Retail Banking Satisfaction StudySM. The study ranked banks doing business in Texas, including regional and large banks.

With an index score of 861 – 33 points higher than the Texas region average – Frost ranked highest in customer satisfaction among all retail banks in Texas. In addition to the top overall ranking, Frost also ranked best in class in the branch, ATM, call center and mobile banking categories.

“Where you bank matters, and that’s especially true after all the events of this past year,” said Frost Chairman and CEO Phil Green. “At Frost, we always stress the importance of building long-term relationships with customers, but the value of that relationship really becomes apparent when times are challenging.

“I’m very proud of our team members for the way they’ve taken care of our customers, our communities, and each other,” Green continued. “This recognition is due to their hard work.”

J.D. Power has studied retail banking for 16 years, but conducted a separate ranking for Texas banks for only 12 years, and Frost has topped the Texas list in all 12. The customer satisfaction study is the longest-running and most in-depth survey of the retail banking industry, with more than 84,000 customers covering various aspects of their banking experience. The study measures satisfaction in six factors: account opening; channel activities; convenience; product/fees; problem resolution; and communication/advice. Banks are ranked based on overall customer satisfaction in 11 regions. 

About Frost:

Frost is the banking, investments and insurance subsidiary of Cullen/Frost Bankers, Inc. (NYSE: CFR), a financial holding company with $42.4 billion in assets at Dec. 31, 2020. One of the 50 largest U.S. banks by asset size, Frost provides a full range of banking, investments and insurance services to businesses and individuals in the Austin, Corpus Christi, Dallas, Fort Worth, Houston, Permian Basin, Rio Grande Valley and San Antonio regions. Founded in 1868, Frost has helped Texans with their financial needs during three centuries. For more information, visit www.frostbank.com.

For more information:
Bill Day
210-220-5427 office
210-288-5498 mobile

 

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/for-12th-year-in-a-row-jd-power-ranks-frost-bank-highest-in-texas-retail-banking-customer-satisfaction-301278360.html

SOURCE Frost